

# Imaging Synaptic Neurotransmission with in Vivo Binding Critical Review

Journal of Cerebral Blood Flow and Metabolism

20, 423-451

DOI: [10.1097/00004647-200003000-00001](https://doi.org/10.1097/00004647-200003000-00001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sensitivity of binding of high-affinity dopamine receptor radioligands to increased synaptic dopamine. <i>Synapse</i> , 2000, 38, 483-488.	0.6	9
2	Cholinergic Neuronal Modulation Alters Dopamine D <sub>2</sub> Receptor Availability <i>In Vivo</i> by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain. <i>Journal of Neuroscience</i> , 2000, 20, 7067-7073.	1.7	91
3	Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 8104-8109.	3.3	955
4	Derivation of [ <sup>11</sup> C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. <i>Nuclear Medicine and Biology</i> , 2000, 27, 487-492.	0.3	58
5	Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. <i>Biological Psychiatry</i> , 2000, 48, 627-640.	0.7	356
6	RPM STATISTICS – A statistical tool for receptor parametric mapping. <i>NeuroImage</i> , 2001, 13, 65.	2.1	2
7	Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. <i>Biological Psychiatry</i> , 2001, 49, 81-96.	0.7	650
8	Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression. <i>Biological Psychiatry</i> , 2001, 50, 313-322.	0.7	126
9	Use of positron emission tomography in analysing receptor function in vivo. <i>Toxicology Letters</i> , 2001, 120, 243-251.	0.4	10
10	Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. <i>Science</i> , 2001, 293, 1164-1166.	6.0	885
11	Dopamine as a Prolactin (PRL) Inhibitor. <i>Endocrine Reviews</i> , 2001, 22, 724-763.	8.9	805
12	Dopamine D2 Receptors in the Insular Cortex and the Personality Trait of Novelty Seeking. <i>NeuroImage</i> , 2001, 13, 891-895.	2.1	167
13	PET in Psychopharmacology. <i>Pharmacological Research</i> , 2001, 44, 151-159.	3.1	17
14	Receptor 1980 and Receptor 2000: twenty years of progress in receptor-binding radiotracers. <i>Nuclear Medicine and Biology</i> , 2001, 28, 475-476.	0.3	15
15	PET/SPECT: functional imaging beyond flow. <i>Vision Research</i> , 2001, 41, 1277-1281.	0.7	35
16	Imaging of dopaminergic transmission in neuropsychiatric disorders. <i>Current Opinion in Psychiatry</i> , 2001, 14, 227-239.	3.1	2
18	Quantifying drug-related 5-HT <sub>1A</sub> receptor occupancy with [ <sup>18</sup> F]MPPF. <i>Psychopharmacology</i> , 2001, 155, 193-197.	1.5	14
20	A consideration of the dopamine D2 receptor monomer-dimer equilibrium and the anomalous binding properties of the dopamine D2 receptor ligand, N-methyl spiperone. <i>Journal of Neural Transmission</i> , 2001, 108, 279-286.	1.4	16

#	ARTICLE	IF	CITATIONS
21	Dopamine Transporter <i>in vitro</i> Binding and <i>in vivo</i> Imaging in the Brain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2001, 88, 287-293.	0.0	12
22	Cholinergic neuronal modulations affect striatal dopamine transporter activity: PET studies in the conscious monkey brain. <i>Synapse</i> , 2001, 42, 193-195.	0.6	15
23	Facilitation of dopaminergic neural transmission does not affect [11C]SCH23390 binding to the striatal D1 dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D1 receptors: PET studies in the conscious monkey brain. <i>Synapse</i> , 2001, 42, 258-265.	0.6	31
24	In vivo binding properties of [carbonyl-11C]WAY-100635: Effect of endogenous serotonin. <i>Synapse</i> , 2001, 40, 122-129.	0.6	55
25	Evaluation of PET ligands (+)N-[11C]ethyl-3-piperidyl benzilate and (+)N-[11C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: A PET study with microdialysis in comparison with (+)N-[11C]methyl-3-piperidyl benzilate in the conscious monkey brain. <i>Synapse</i> , 2001, 40, 159-169.	0.6	29
26	Effect of endogenous dopamine on extrastriatal [11C]FLB 457 binding measured by PET. <i>Synapse</i> , 2001, 41, 87-95.	0.6	60
27	Effect of 5-HT on binding of [11C] WAY 100635 to 5-HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. <i>Synapse</i> , 2001, 41, 150-159.	0.6	80
28	The neurochemistry of therapeutics: Levodopa pharmacodynamics in Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 285-287.	2.8	10
29	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001, 49, 298-303.	2.8	205
30	A novel iodinated benzamide derivative for imaging endogenous dopamine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S225.	0.5	0
31	Acetylcholinesterase Inhibition Increases in Vivo N-(2-[18F]Fluoroethyl)-4-piperidyl Benzilate Binding to Muscarinic Acetylcholine Receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 144-148.	2.4	12
32	Absolute Quantification by Positron Emission Tomography of the Endogenous Ligand. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 613-630.	2.4	29
33	Positron Emission Tomography Compartmental Models. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 635-652.	2.4	470
34	Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1034-1057.	2.4	493
35	Measurement of Cortical Dopamine D1 Receptor Binding with [11C]SCH 23390: A Test-Retest Analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1146-1150.	2.4	28
36	Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1151-1159.	2.4	52
37	Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans. <i>Neuropsychopharmacology</i> , 2001, 24, 209-229.	2.8	112
38	The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. <i>Neuropsychopharmacology</i> , 2001, 24, 553-560.	2.8	171

#	ARTICLE	IF	CITATIONS
39	A Simple Method to Measure Baseline Occupancy of Neostriatal Dopamine D2 Receptors by Dopamine In Vivo in Healthy Subjects. <i>Neuropsychopharmacology</i> , 2001, 25, 213-223.	2.8	63
40	Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride. <i>Neuropsychopharmacology</i> , 2001, 25, 476-488.	2.8	71
41	Effects of Endogenous Neurotransmitters on the in vivo Binding of Dopamine and 5-HT Radiotracers in Mice. <i>Neuropsychopharmacology</i> , 2001, 25, 679-689.	2.8	23
42	Neurobiological Mechanisms of Social Anxiety Disorder. <i>American Journal of Psychiatry</i> , 2001, 158, 1558-1567.	4.0	148
43	Imaging neurochemical endophenotypes: promises and pitfalls. <i>Pharmacogenomics</i> , 2001, 2, 223-237.	0.6	25
44	Rezeptordarstellung mit der Positronen-Emissions-Tomographie - Anwendung in Klinik und Forschung - Aktuelle Neurologie, 2002, 29, 1-11.	0.1	0
45	Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans. <i>Molecular Psychiatry</i> , 2002, 7, 322-328.	4.1	43
46	Imaging the neurochemical brain in health and disease. <i>Clinical Medicine</i> , 2002, 2, 67-73.	0.8	16
47	Decreased Dopamine D2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia. <i>Archives of General Psychiatry</i> , 2002, 59, 25.	13.8	173
48	Human Microdialysis. <i>Current Pharmaceutical Biotechnology</i> , 2002, 3, 165-178.	0.9	55
49	Elevated Intrasympaptic Dopamine Release in Tourette's Syndrome Measured by PET. <i>American Journal of Psychiatry</i> , 2002, 159, 1329-1336.	4.0	236
50	Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. <i>Biological Psychiatry</i> , 2002, 51, 715-722.	0.7	145
51	Age-related decline of serotonin transporters in living human brain of healthy males. <i>Life Sciences</i> , 2002, 71, 751-757.	2.0	83
52	A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. <i>NeuroImage</i> , 2002, 15, 620-632.	2.1	133
53	In Vivo Detection of Striatal Dopamine Release during Reward: A PET Study with [11C]Raclopride and a Single Dynamic Scan Approach. <i>NeuroImage</i> , 2002, 16, 1015-1027.	2.1	115
54	Measuring drug-related receptor occupancy with positron emission tomography. <i>Methods</i> , 2002, 27, 278-286.	1.9	63
55	Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. <i>Pain</i> , 2002, 99, 273-279.	2.0	129
56	Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). <i>Pain</i> , 2002, 99, 589-598.	2.0	116

#	ARTICLE	IF	CITATIONS
57	MR atlas of the baboon brain for functional neuroimaging. Brain Research Bulletin, 2002, 58, 429-438.	1.4	36
58	Functional Imaging of the Dopamine System: In Vivo Evaluation of Dopamine Deficiency and Restoration. NeuroToxicology, 2002, 23, 469-478.	1.4	14
59	The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behavioural Brain Research, 2002, 130, 57-63.	1.2	99
62	$\mu$ -Opioid Receptor-Mediated Antinociceptive Responses Differ in Men and Women. Journal of Neuroscience, 2002, 22, 5100-5107.	1.7	344
63	Prefrontal Dopamine D <sub>1</sub> Receptors and Working Memory in Schizophrenia. Journal of Neuroscience, 2002, 22, 3708-3719.	1.7	688
64	Increment of in vivo binding of [3H]SCH 23390, a dopamine D1 receptor ligand, induced by cyclic AMP-dependent protein kinase in rat brain. Brain Research, 2002, 952, 211-217.	1.1	4
65	Effects of Amphetamine and Evoked Dopamine Release on [11C]raclopride Binding in Anesthetized Cats. Neuropsychopharmacology, 2002, 27, 72-84.	2.8	23
66	Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride. Neuropsychopharmacology, 2002, 27, 248-259.	2.8	261
67	Amphetamine-Induced Increases in Extracellular Dopamine, Drug Wanting, and Novelty Seeking A PET/[11C]Raclopride Study in Healthy Men. Neuropsychopharmacology, 2002, 27, 1027-1035.	2.8	404
68	Neuroreceptor imaging in psychiatric disorders. Annals of Nuclear Medicine, 2002, 16, 437-446.	1.2	54
69	Ketamine does not decrease striatal dopamine D <sub>2</sub> receptor binding in man. Psychopharmacology, 2002, 164, 401-406.	1.5	65
70	The potential of the $^{125}$ I-Microprobe, an intracerebral radiosensitive probe, to monitor the [18F]MPPF binding in the rat dorsal raphe nucleus. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1237-1247.	3.3	27
71	New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [11C]raclopride study. Journal of Neural Transmission, 2002, 109, 1265-1274.	1.4	32
72	Effect of endogenous serotonin on the binding of the 5-HT <sub>1A</sub> PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. Journal of Neurochemistry, 2002, 80, 278-286.	2.1	78
73	NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse, 2002, 43, 19-29.	0.6	91
74	Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse, 2002, 43, 181-187.	0.6	273
75	Demonstration of competition between endogenous dopamine and [11C]raclopride binding in in vitro brain slices using a dynamic autoradiography technique. Synapse, 2002, 44, 42-50.	0.6	14
76	?Nonhedonic? food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse, 2002, 44, 175-180.	0.6	400

#	ARTICLE	IF	CITATIONS
77	(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor. <i>Synapse</i> , 2002, 45, 31-37.	0.6	15
78	Age-related changes in the striatal dopaminergic system in the living brain: A multiparametric PET study in conscious monkeys. <i>Synapse</i> , 2002, 45, 38-45.	0.6	41
79	Comparative effects of methamphetamine and nicotine on the striatal [11C]raclopride binding in unanesthetized monkeys. <i>Synapse</i> , 2002, 45, 207-212.	0.6	90
80	5-HT1A receptor imaging in the human brain: Effect of tryptophan depletion and infusion on [18F]MPPF binding. <i>Synapse</i> , 2002, 46, 108-115.	0.6	43
81	In Vivo Receptor Assay with Multiple Ligand Concentrations: An Equilibrium Approach. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1132-1141.	2.4	33
82	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1425-1439.	2.4	181
83	Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. <i>Nature Neuroscience</i> , 2002, 5, 169-174.	7.1	645
84	Occupancy of dopamine D 2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and [ 123 I]IBF. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1507-1515.	3.3	58
85	Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 364-367.	1.8	13
86	Glutamate, Dopamine, and Schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 138-158.	1.8	409
87	PET study of the [ 11 C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 141-148.	3.3	64
88	Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. <i>Psychopharmacology</i> , 2003, 166, 264-270.	1.5	89
89	Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, 1219-1223.	1.8	49
90	Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls. <i>Psychiatry Research - Neuroimaging</i> , 2003, 123, 191-197.	0.9	47
91	Endogenous dopamine release in Parkinson's disease. <i>Lancet Neurology</i> , The, 2003, 2, 460-461.	4.9	2
92	Soluble oligomers for the diagnosis of neurodegenerative diseases. <i>Lancet Neurology</i> , The, 2003, 2, 461-462.	4.9	44
93	Brain dopamine is associated with eating behaviors in humans. <i>International Journal of Eating Disorders</i> , 2003, 33, 136-142.	2.1	197
94	Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. <i>Movement Disorders</i> , 2003, 18, 41-48.	2.2	146

#	ARTICLE	IF	CITATIONS
95	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 53, 647-653.	2.8	149
96	Visualization of $\alpha 5$ subunit of GABAA/benzodiazepine receptor by [ $^{11}\text{C}$ ]Ro15-4513 using positron emission tomography. <i>Synapse</i> , 2003, 47, 200-208.	0.6	33
97	Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [ $^{123}\text{I}$ ]5-I-A-85380. <i>Synapse</i> , 2003, 48, 116-122.	0.6	23
98	Alcohol promotes dopamine release in the human nucleus accumbens. <i>Synapse</i> , 2003, 49, 226-231.	0.6	482
99	Dopamine displaces [ $^3\text{H}$ ]domperidone from high-affinity sites of the dopamine D2 receptor, but not [ $^3\text{H}$ ]raclopride or [ $^3\text{H}$ ]spiperone in isotonic medium: Implications for human positron emission tomography. <i>Synapse</i> , 2003, 49, 209-215.	0.6	91
100	Displacement of the PET ligand 18F-MPPF by the electrically evoked serotonin release in the rat hippocampus. <i>Synapse</i> , 2003, 49, 239-245.	0.6	29
101	Intrastriatal microinjection of sodium nitroprusside induces cell death and reduces binding of dopaminergic receptors. <i>Synapse</i> , 2003, 50, 137-143.	0.6	8
102	Fenfluramine evokes 5-HT <sub>2A</sub> receptor-mediated responses but does not displace [ $^{11}\text{C}$ ]MDL 100907: Small animal PET and gene expression studies. <i>Synapse</i> , 2003, 50, 251-260.	0.6	40
103	Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 285-300.	2.4	510
104	<i>In Vivo</i> Measurement of Receptor Density and Affinity: Comparison of the Routine Sequential Method with a Nonsequential Method in Studies of Dopamine D <sub>2</sub> Receptors with [ $^{11}\text{C}$ ]Raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 280-284.	2.4	10
105	Sequential Versus Nonsequential Measurement of Density and Affinity of Dopamine D <sub>2</sub> Receptors with [ $^{11}\text{C}$ ]raclopride: Effect of Methamphetamine. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1489-1494.	2.4	19
106	Principles of tracer kinetic analysis. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 689-704.	0.5	14
107	Effects of acute nicotine on hemodynamics and binding of [ $^{11}\text{C}$ ]raclopride to dopamine D <sub>2,3</sub> receptors in pig brain. <i>NeuroImage</i> , 2003, 19, 1127-1136.	2.1	64
108	Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. <i>NeuroImage</i> , 2003, 19, 1709-1715.	2.1	522
109	Raclopride studies of dopamine release: dependence on presynaptic integrity. <i>Biological Psychiatry</i> , 2003, 54, 1193-1199.	0.7	22
110	Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naïve healthy volunteers: results from a large cohort. <i>European Neuropsychopharmacology</i> , 2003, 13, 459-468.	0.3	60
111	Imaging methods for evaluating brain function in man. <i>Neurobiology of Aging</i> , 2003, 24, S21-S35.	1.5	50
112	Altered dopamine D <sub>2</sub> receptor binding in atypical facial pain. <i>Pain</i> , 2003, 106, 43-48.	2.0	181

#	ARTICLE	IF	CITATIONS
113	Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man. Behavioural Brain Research, 2003, 139, 21-29.	1.2	26
114	Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Seminars in Nuclear Medicine, 2003, 33, 2-13.	2.5	63
115	Radiotracers for positron emission tomography imaging. Seminars in Nuclear Medicine, 2003, 33, 14-27.	2.5	41
116	Phenylephrine and norepinephrine increase dopamine transporter ligand binding in striatum. Molecular Imaging and Biology, 2003, 5, 217-226.	1.3	2
117	Kinetics of the uptake and distribution of the dopamine D2,3 agonist (R)-N-[1-11C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs. Nuclear Medicine and Biology, 2003, 30, 547-553.	0.3	31
118	Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia. Neuroscientist, 2003, 9, 404-416.	2.6	243
119	Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clinics of North America, 2003, 13, 817-832.	0.5	26
120	Positron emission tomography radiochemistry. Neuroimaging Clinics of North America, 2003, 13, 671-687.	0.5	10
121	Regulation of Human Affective Responses by Anterior Cingulate and Limbic $\mu$ -Opioid Neurotransmission. Archives of General Psychiatry, 2003, 60, 1145.	13.8	345
122	Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain, 2003, 126, 2609-2615.	3.7	478
123	In Vivo Evidence for Dopamine-Mediated Internalization of D2-Receptors after Amphetamine: Differential Findings with [3H]Raclopride versus [3H]Spiperone. Molecular Pharmacology, 2003, 63, 456-462.	1.0	98
124	Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia. Neuropsychopharmacology, 2003, 28, 1703-1711.	2.8	83
125	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. Neurosurgery, 2003, 53, 1095-1105.	0.6	76
126	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain, 2003, 126, 312-325.	3.7	90
127	Positron emission tomography (PET) neurochemistry: where are we now and where are we going?. , 2003, , 181-194.		1
128	Kinetic Modeling in Positron Emission Tomography. , 2004, , 499-540.		91
129	Positron Emission Tomography Receptor Assay with Multiple Ligand Concentrations: An Equilibrium Approach. Methods in Enzymology, 2004, 385, 169-184.	0.4	4
130	Nicotine-Induced Dopamine Release in Primates Measured with [11C]Raclopride PET. Neuropsychopharmacology, 2004, 29, 259-268.	2.8	57



#	ARTICLE	IF	CITATIONS
131	Presynaptic Dopaminergic Dysfunction in Schizophrenia. Archives of General Psychiatry, 2004, 61, 134.	13.8	214
133	Smoking-Induced Ventral Striatum Dopamine Release. American Journal of Psychiatry, 2004, 161, 1211-1218.	4.0	298
134	Dopamine Transmission in the Human Striatum during Monetary Reward Tasks. Journal of Neuroscience, 2004, 24, 4105-4112.	1.7	210
135	Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain. European Journal of Neuroscience, 2004, 20, 1587-1592.	1.2	74
136	DASB -invitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer. Journal of Neurochemistry, 2004, 90, 1218-1226.	2.1	37
137	In vivo Binding Behavior of Dopamine Receptor Agonist (+)-PD 128907 and Implications for the "Ceiling Effect" in Endogenous Competition Studies with [ <sup>11</sup> C]Raclopride: A Positron Emission Tomography Study in Macaca mulatta. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 531-535.	2.4	20
138	[ <sup>18</sup> F]altanserin Binding to Human 5HT <sub>2A</sub> Receptors is Unaltered after Citalopram and Pindolol Challenge. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1037-1045.	2.4	42
139	Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2004, 131, 209-216.	0.9	37
140	Striatal dopamine D2 receptors in modulation of pain in humans: a review. European Journal of Pharmacology, 2004, 500, 187-192.	1.7	199
141	Striatal dopamine D <sub>2</sub> receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an [ <sup>123</sup> I]IBZM-SPECT study. Psychopharmacology, 2004, 172, 165-169.	1.5	18
142	[N-methyl- <sup>11</sup> C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology, 2004, 174, 260-5.	1.5	13
143	In vivo affinity of [ <sup>18</sup> F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology, 2004, 175, 274-286.	1.5	63
144	Oral D-amphetamine causes prolonged displacement of [ <sup>11</sup> C]raclopride as measured by PET. Synapse, 2004, 51, 27-31.	0.6	55
145	Tyrosine-free amino acid mixture attenuates amphetamine-induced displacement of [ <sup>11</sup> C]raclopride in striatum in vivo: A rat PET study. Synapse, 2004, 51, 151-157.	0.6	15
146	Temporal characterisation of amphetamine-induced dopamine release assessed with [ <sup>11</sup> C]raclopride in anaesthetised rodents. Synapse, 2004, 51, 206-212.	0.6	47
147	Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 2004, 52, 1-10.	0.6	59
148	Quantitative validation of an intracerebral $\alpha$ -sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [ <sup>11</sup> C]raclopride in rats. Synapse, 2004, 52, 89-99.	0.6	24
149	ADAM is an effective tool for in vivo study of serotonergic function: Validation in rat models. Synapse, 2004, 52, 136-142.	0.6	11

#	ARTICLE	IF	CITATIONS
150	In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. <i>Synapse</i> , 2004, 52, 188-208.	0.6	145
151	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. <i>Synapse</i> , 2004, 53, 222-233.	0.6	36
152	Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. <i>Synapse</i> , 2004, 54, 46-63.	0.6	61
153	Parkinson's prevalence estimated by a state registry. <i>Movement Disorders</i> , 2004, 19, 318-323.	2.2	87
154	Cardiovascular effects of methamphetamine in Parkinson's disease patients. <i>Movement Disorders</i> , 2004, 19, 298-303.	2.2	13
155	Health-related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ-8 and EuroQoL-5D. <i>Movement Disorders</i> , 2004, 19, 312-318.	2.2	52
156	Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. <i>Movement Disorders</i> , 2004, 19, 303-308.	2.2	96
157	Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. <i>Movement Disorders</i> , 2004, 19, 324-330.	2.2	28
158	Assessing quality of life in Parkinson's disease: Can a short-form questionnaire be useful?. <i>Movement Disorders</i> , 2004, 19, 308-312.	2.2	45
159	Mapping brain function in freely moving subjects. <i>Neuroscience and Biobehavioral Reviews</i> , 2004, 28, 449-461.	2.9	20
160	PET Measurement of rCBF in the presence of a neurochemical tracer. <i>Journal of Neuroscience Methods</i> , 2004, 132, 199-208.	1.3	16
161	Quantification in PET. <i>Radiologic Clinics of North America</i> , 2004, 42, 1055-1062.	0.9	48
162	Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. <i>Biological Psychiatry</i> , 2004, 55, 1001-1006.	0.7	126
163	Amphetamine pretreatment induces a change in both D 2 -Receptor density and apparent affinity: a [ 11 C]raclopride positron emission tomography study in cats. <i>Biological Psychiatry</i> , 2004, 55, 1188-1194.	0.7	40
164	Molecular Imaging of Biological Processes with PET: Evaluating Biologic Bases of Cerebral Function. , 2004, , 509-583.		11
165	Applications of positron emission tomography (PET) in neurology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 669-676.	0.9	98
166	Dopamine Release in Response to a Psychological Stress in Humans and Its Relationship to Early Life Maternal Care: A Positron Emission Tomography Study Using [11C]Raclopride. <i>Journal of Neuroscience</i> , 2004, 24, 2825-2831.	1.7	622
167	PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. <i>Experimental Neurology</i> , 2004, 189, 361-368.	2.0	50

#	ARTICLE	IF	CITATIONS
168	Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects. <i>Pain</i> , 2004, 109, 86-93.	2.0	35
169	A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123i]CNS 1261. <i>Nuclear Medicine and Biology</i> , 2004, 31, 155-164.	0.3	30
170	Sensitivity of [11C]N-methylpyrrolidiny benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods. <i>Nuclear Medicine and Biology</i> , 2004, 31, 393-397.	0.3	13
171	Effect of sensory stimulus on striatal dopamine release in humans and cats: a [11C]raclopride PET study. <i>Neuroscience Letters</i> , 2004, 368, 46-51.	1.0	6
172	Kinetic analysis of neuroreceptor binding using PET. <i>International Congress Series</i> , 2004, 1265, 12-24.	0.2	7
173	Role of human and animal PET studies in drug development. <i>International Congress Series</i> , 2004, 1265, 3-11.	0.2	7
174	PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. <i>NeuroImage</i> , 2004, 23, 1-16.	2.1	90
175	NeuroReceptor Mapping 2004 Poster Presentation. <i>NeuroImage</i> , 2004, 22, T61-T200.	2.1	2
176	Neurodegenerative movement disorders: the contribution of functional imaging. <i>Current Opinion in Neurology</i> , 2004, 17, 459-466.	1.8	20
177	Reduction of serotonin transporters of patients with chronic fatigue syndrome. <i>NeuroReport</i> , 2004, 15, 2571-2574.	0.6	111
178	Dopaminergic effects of caffeine in the human striatum and thalamus. <i>NeuroReport</i> , 2004, 15, 281-285.	0.6	57
179	Chapter 8 Sorption (binding) and transport phenomena in biomembranes. <i>Interface Science and Technology</i> , 2004, , 215-277.	1.6	2
180	Increased Caudate Dopamine D2 Receptor Availability as a Genetic Marker for Schizophrenia. <i>Archives of General Psychiatry</i> , 2005, 62, 371.	13.8	142
181	Correlation between different memory systems and striatal dopamine D2/D3 receptor density: a single photon emission computed tomography study. <i>Psychological Medicine</i> , 2005, 35, 197-204.	2.7	42
182	What to learn from in vivo opioidergic brain imaging?. <i>European Journal of Pain</i> , 2005, 9, 117-121.	1.4	67
183	Syntheses, Biological Evaluation, and Molecular Modeling of 18F-Labeled 4-Anilidopiperidines as $\mu$ -Opioid Receptor Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7720-7732.	2.9	32
184	Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. <i>Brain Research</i> , 2005, 1032, 77-84.	1.1	57
185	Brain imaging research on subjective responses to psychotropic drugs. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 22-28.	2.2	35

#	ARTICLE	IF	CITATIONS
186	Correlation between striatal dopamine D2 receptor density and neuroticism in community volunteers. <i>Psychiatry Research - Neuroimaging</i> , 2005, 138, 259-264.	0.9	35
187	Synthesis of (R)-(-)-2-Fluoronorapomorphine – A Precursor for the Synthesis of (R)-(-)-2-Fluoro-N-[11C]propylnorapomorphine for Evaluation as a Dopamine D2 Agonist Ligand for PET Investigations. <i>European Journal of Organic Chemistry</i> , 2005, 2005, 4428-4433.	1.2	16
189	[123I]Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine – an in vivo imaging study with a dedicated small animal SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1305-1310.	3.3	26
190	Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. <i>Psychopharmacology</i> , 2005, 180, 705-715.	1.5	84
191	Cortical glutamate – dopamine interaction and ketamine-induced psychotic symptoms in man. <i>Psychopharmacology</i> , 2005, 182, 375-383.	1.5	81
192	Assessment of methylphenidate-induced changes in binding of continuously infused [11C]-raclopride in healthy human subjects: correlation with subjective effects. <i>Psychopharmacology</i> , 2005, 183, 322-330.	1.5	13
193	Imaging the Dopamine System with In Vivo [11C]raclopride Displacement Studies: Understanding the True Mechanism. <i>Molecular Imaging and Biology</i> , 2005, 7, 45-52.	1.3	68
194	Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002. <i>Synapse</i> , 2005, 55, 126-132.	0.6	7
195	Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand [11C]-DASB in healthy humans. <i>Synapse</i> , 2005, 55, 164-175.	0.6	81
196	The effect of a 5-HT1A receptor agonist on striatal dopamine release. <i>Synapse</i> , 2005, 57, 67-75.	0.6	26
197	Nicotine modulates dopamine synthesis rate as determined by L-[12-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain. <i>Synapse</i> , 2005, 57, 120-122.	0.6	13
198	Acute NMDA receptor antagonism induces biphasic striatal utilization of L-[12-11C]DOPA: PET studies in the conscious monkey brain. <i>Synapse</i> , 2005, 57, 116-119.	0.6	5
199	Nicotine Normalizes Increased Prefrontal Cortical Dopamine D1 Receptor Binding and Decreased Working Memory Performance Produced by Repeated Pretreatment with MK-801: A PET Study in Conscious Monkeys. <i>Neuropsychopharmacology</i> , 2005, 30, 2144-2153.	2.8	33
200	Pharmacokinetic-Pharmacodynamic Analysis of Antipsychotics-induced Extrapyramidal Symptoms based on Receptor Occupancy Theory Incorporating Endogenous Dopamine Release. <i>Drug Metabolism and Pharmacokinetics</i> , 2005, 20, 187-199.	1.1	29
201	PET Imaging of Dopamine D2 Receptors in Monkey Models of Cocaine Abuse: Genetic Predisposition Versus Environmental Modulation. <i>American Journal of Psychiatry</i> , 2005, 162, 1473-1482.	4.0	154
202	Correlation of Alcohol Craving With Striatal Dopamine Synthesis Capacity and D2/3 Receptor Availability: A Combined [18F]DOPA and [18F]DMFP PET Study in Detoxified Alcoholic Patients. <i>American Journal of Psychiatry</i> , 2005, 162, 1515-1520.	4.0	253
203	Effect of Increased Serotonin Levels on [18F]MPPF Binding in Rat Brain: Fenfluramine vs the Combination of Citalopram and Ketanserin. <i>Neuropsychopharmacology</i> , 2005, 30, 1624-1631.	2.8	25
204	Mapping Neuroreceptors at work: on the Definition and Interpretation of Binding Potentials after 20 years of Progress. <i>International Review of Neurobiology</i> , 2005, 63, 1-20.	0.9	52

#	ARTICLE	IF	CITATIONS
205	Tracer Kinetic Modeling in PET. , 2005, , 127-159.		91
206	Frontal and Temporal Dopamine Release during Working Memory and Attention Tasks in Healthy Humans: a Positron Emission Tomography Study Using the High-Affinity Dopamine D2 Receptor Ligand [ <sup>11</sup> C]FLB 457. Journal of Neuroscience, 2005, 25, 2471-2477.	1.7	261
207	Differential in vivo Inhibition of [ <sup>3</sup> H]Nemonapride Binding by Atypical Antipsychotics in Rat Striatum, Olfactory Lobes, and Frontal Cortex. Pharmacology, 2005, 75, 63-68.	0.9	7
208	MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage, 2005, 24, 969-979.	2.1	327
209	Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. NeuroImage, 2005, 25, 868-876.	2.1	122
210	Differential effects of paroxetine on raphe and cortical 5-HT <sub>1A</sub> binding: A PET study in monkeys. NeuroImage, 2005, 28, 238-248.	2.1	27
211	Cortico-striatal functional interactions in Parkinson's disease: a rTMS/[ <sup>11</sup> C]raclopride PET study. European Journal of Neuroscience, 2005, 22, 2946-2952.	1.2	153
213	Positron-Labeled Dopamine Agonists for Probing the High Affinity States of Dopamine Subtype 2 Receptors. Bioconjugate Chemistry, 2005, 16, 27-31.	1.8	22
214	Radiosynthesis and Evaluation of [ <sup>11</sup> C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography. Journal of Medicinal Chemistry, 2005, 48, 4153-4160.	2.9	218
215	Striatal dopamine during sensorial stimulations: A [ <sup>18</sup> F]FDOPA PET study in human and cats. Neuroscience Letters, 2005, 383, 63-67.	1.0	2
216	Alteration of striatal [ <sup>11</sup> C]raclopride and 6-[ <sup>18</sup> F]fluoro-l-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats. Neuroscience Letters, 2005, 389, 30-34.	1.0	14
217	Behavioral response to novelty correlates with dopamine receptor availability in striatum of GÅtttingen minipigs. Behavioural Brain Research, 2005, 164, 172-177.	1.2	25
218	Mapping the amphetamine-evoked dopamine release in the brain of the GÅtttingen minipig. Brain Research Bulletin, 2005, 65, 1-9.	1.4	27
219	Interface of physical and emotional stress regulation through the endogenous opioid system and $\mu$ -opioid receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1264-1280.	2.5	132
220	High-frequency stimulation in Parkinson's disease: more or less?. Trends in Neurosciences, 2005, 28, 209-216.	4.2	220
221	Potential of [ <sup>11</sup> C]DASB for measuring endogenous serotonin with PET: binding studies. Nuclear Medicine and Biology, 2005, 32, 129-136.	0.3	28
222	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx, 2005, 2, 226-236.	6.0	97
223	Electroconvulsive shock decreases binding to 5-HT <sub>2</sub> receptors in nonhuman primates: An in vivo positron emission tomography study with [ <sup>18</sup> F]setoperone. Biological Psychiatry, 2005, 57, 1004-1010.	0.7	42

#	ARTICLE	IF	CITATIONS
224	PET studies in drug development: Methodological considerations. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 311-315.	4.0	34
225	Imaging of the Brain Cannabinoid System. , 2005, , 425-443.		10
226	Neuroreceptor Imaging in Psychiatry: Theory and Applications. <i>International Review of Neurobiology</i> , 2005, 67, 385-440.	0.9	15
228	Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy. <i>NeuroImage</i> , 2006, 30, 341-348.	2.1	47
229	Simplified reference tissue approach with multiple injections of [C-11]raclopride. <i>NeuroImage</i> , 2006, 31, T72.	2.1	0
230	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. <i>NeuroImage</i> , 2006, 33, 550-563.	2.1	42
231	Striatal dopamine release during performance of executive functions: A [11C] raclopride PET study. <i>NeuroImage</i> , 2006, 33, 907-912.	2.1	109
232	PET neuroimaging of [11C]mirtazapine enantiomers in pigs. <i>European Neuropsychopharmacology</i> , 2006, 16, 350-357.	0.3	10
233	The association between the Lie scale of the Maudsley personality inventory and striatal dopamine D2/D3 receptor availability of healthy Chinese community subjects. <i>European Psychiatry</i> , 2006, 21, 62-65.	0.1	21
234	Applications of Clinical Dopamine Imaging. <i>Neuroimaging Clinics of North America</i> , 2006, 16, 553-573.	0.5	4
235	Imaging in Parkinson's Disease: The Role of Monoamines in Behavior. <i>Biological Psychiatry</i> , 2006, 59, 908-918.	0.7	136
236	Sex Differences in Striatal Dopamine Release in Healthy Adults. <i>Biological Psychiatry</i> , 2006, 59, 966-974.	0.7	315
237	Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function. <i>Biological Psychiatry</i> , 2006, 59, 898-907.	0.7	258
238	Correlation Between Striatal Dopamine D2/D3 Receptor Binding and Cardiovascular Activity in Healthy Subjects. <i>American Journal of Hypertension</i> , 2006, 19, 964-969.	1.0	24
239	Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. <i>Experimental Neurology</i> , 2006, 202, 381-390.	2.0	170
240	Belief or Need? Accounting for individual variations in the neurochemistry of the placebo effect. <i>Brain, Behavior, and Immunity</i> , 2006, 20, 15-26.	2.0	97
241	Inhibition of serotonin transport by (+)McN5652 is noncompetitive. <i>Nuclear Medicine and Biology</i> , 2006, 33, 317-323.	0.3	8
243	Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. <i>Nuclear Medicine Communications</i> , 2006, 27, 267-270.	0.5	51

#	ARTICLE	IF	CITATIONS
244	Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeys. <i>Synapse</i> , 2006, 59, 18-26.	0.6	40
245	Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain—An ex vivo study. <i>Synapse</i> , 2006, 59, 162-172.	0.6	9
246	Quantitative autoradiography of ligands for dopamine receptors and transporters in brain of GÅttingen minipig: Comparison with results in vivo. <i>Synapse</i> , 2006, 59, 211-219.	0.6	27
247	Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. <i>Synapse</i> , 2006, 59, 243-251.	0.6	109
248	Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. <i>Synapse</i> , 2006, 59, 260-269.	0.6	108
249	Age and APOE-Î4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. <i>Synapse</i> , 2006, 60, 86-92.	0.6	18
250	In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. <i>Synapse</i> , 2006, 60, 172-183.	0.6	24
251	Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. <i>Synapse</i> , 2006, 60, 314-318.	0.6	11
252	Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2006, 23, 1005-1014.	1.2	133
253	Methylphenidate—Evoked Potentiation of Extracellular Dopamine in the Brain of Adolescents with Premature Birth. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 434-439.	1.8	47
254	PET Studies on the Function of Dopamine in Health and Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 22-35.	1.8	34
255	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , 2006, 97, 1089-1103.	2.1	145
256	Striatal Dopamine Release and Family History of Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2006, 30, 1143-1151.	1.4	41
257	Sequential versus Nonsequential Measurement of Density and Affinity of Dopamine D2 Receptors with [11C]Raclopride: 2: Effects of DAT Inhibitors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 28-37.	2.4	4
258	Why does the agonist [18F]FP-TZTP bind preferentially to the M2 muscarinic receptor?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 292-300.	3.3	12
259	Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. <i>Psychopharmacology</i> , 2006, 190, 241-249.	1.5	49
260	Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. <i>European Journal of Pharmacology</i> , 2006, 540, 87-90.	1.7	22
261	Brain imaging of clinical pain states: a critical review and strategies for future studies. <i>Lancet Neurology</i> , The, 2006, 5, 1033-1044.	4.9	100

#	ARTICLE	IF	CITATIONS
262	Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: Preliminary results of a dynamic [ <sup>123</sup> I] IBZM SPECT study. <i>Journal of Psychiatric Research</i> , 2006, 40, 307-314.	1.5	161
263	Striatal dopamine D2/D3 receptor availability in male smokers. <i>Psychiatry Research - Neuroimaging</i> , 2006, 146, 87-90.	0.9	21
264	Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2006, 146, 13-20.	0.9	30
265	Recent development and potential use of $\mu$ - and $\delta$ -opioid receptor ligands in positron emission tomography studies. <i>Drug Development Research</i> , 2006, 67, 890-904.	1.4	9
266	New developments of brain imaging for Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2006, 21, 2035-2041.	2.2	34
267	Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography. <i>Neuropsychopharmacology</i> , 2006, 31, 967-977.	2.8	40
268	Amphetamine-Induced Displacement of [ <sup>18</sup> F] Fallypride in Striatum and Extrastriatal Regions in Humans. <i>Neuropsychopharmacology</i> , 2006, 31, 1016-1026.	2.8	124
269	Neurotransmitter Imaging. , 2006, , 385-403.		2
270	The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain. <i>Current Pharmaceutical Design</i> , 2006, 12, 3877-900.	0.9	56
271	Chapter 1.1 What did we learn from microdialysis?. <i>Handbook of Behavioral Neuroscience</i> , 2006, , 5-16.	0.7	3
272	Functional Pharmacology in Human Brain. <i>Pharmacological Reviews</i> , 2006, 58, 162-193.	7.1	59
273	Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. <i>Neurology</i> , 2006, 67, 1612-1617.	1.5	173
274	Modeling Sensitization to Stimulants in Humans. <i>Archives of General Psychiatry</i> , 2006, 63, 1386-95.	13.8	255
275	Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. <i>Current Psychiatry Reviews</i> , 2006, 2, 111-149.	0.9	25
276	Elevated Putamen D <sub>2</sub> Receptor Binding Potential in Major Depression With Motor Retardation: An [ <sup>11</sup> C]Raclopride Positron Emission Tomography Study. <i>American Journal of Psychiatry</i> , 2006, 163, 1594-1602.	4.0	139
277	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. <i>Brain</i> , 2006, 129, 2017-2028.	3.7	224
278	Smoking Modulation of $\mu$ -Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans. <i>Neuropsychopharmacology</i> , 2007, 32, 450-457.	2.8	115
279	Task-Related Interaction between Basal Ganglia and Cortical Dopamine Release. <i>Journal of Neuroscience</i> , 2007, 27, 14434-14441.	1.7	41



#	ARTICLE	IF	CITATIONS
280	Fluvoxamine Treatment and D2 Receptors: a Pet Study on OCD Drug-Naïve Patients. <i>Neuropsychopharmacology</i> , 2007, 32, 197-205.	2.8	65
281	Neuroreceptor Imaging Studies in Schizophrenia. <i>Harvard Review of Psychiatry</i> , 2007, 15, 212-232.	0.9	24
282	Functional Imaging of Neurotransmission. <i>Current Medical Imaging</i> , 2007, 3, 220-224.	0.4	4
283	Dopamine, Prefrontal Cortex and Working Memory Functioning in Schizophrenia. <i>Pharmacopsychiatry</i> , 2007, 40, S62-S72.	1.7	6
284	Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. <i>Journal of Psychopharmacology</i> , 2007, 21, 253-258.	2.0	31
285	Conditioned Dopamine Release in Humans: A Positron Emission Tomography [ <sup>11</sup> C]Raclopride Study with Amphetamine. <i>Journal of Neuroscience</i> , 2007, 27, 3998-4003.	1.7	199
286	Investigating the Dopaminergic Synapse In Vivo. I. Molecular Imaging Studies in Humans. <i>Reviews in the Neurosciences</i> , 2007, 18, 439-72.	1.4	46
287	PET and SPECT Imaging in Psychiatric Disorders. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 146-157.	0.9	79
289	The relation between striatal dopamine D2/D3 receptor availability and sleep quality in healthy adults. <i>Nuclear Medicine Communications</i> , 2007, 28, 401-406.	0.5	7
290	Amphetamine-Induced Dopamine Release: Markedly Blunted in Cocaine Dependence and Predictive of the Choice to Self-Administer Cocaine. <i>American Journal of Psychiatry</i> , 2007, 164, 622-629.	4.0	345
291	Conditioned and sensitized responses to stimulant drugs in humans. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1601-1613.	2.5	110
292	Effect of aging on cerebral A1 adenosine receptors: A [ <sup>18</sup> F]CPFPX PET study in humans. <i>Neurobiology of Aging</i> , 2007, 28, 1914-1924.	1.5	63
293	[ <sup>18</sup> F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. <i>Neuropharmacology</i> , 2007, 52, 695-707.	2.0	79
294	Stereoselective neuroimaging in vivo. <i>European Neuropsychopharmacology</i> , 2007, 17, 507-522.	0.3	10
295	Striatal dopamine (D2) receptor availability predicts socially desirable responding. <i>NeuroImage</i> , 2007, 34, 1782-1789.	2.1	43
296	Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. <i>NeuroImage</i> , 2007, 36, 153-166.	2.1	93
297	Neurobiology of Dopamine in Schizophrenia. <i>International Review of Neurobiology</i> , 2007, 78, 1-39.	0.9	275
298	Cutting-Edge Brain Imaging with Positron Emission Tomography. <i>Neuroimaging Clinics of North America</i> , 2007, 17, 427-440.	0.5	7

#	ARTICLE	IF	CITATIONS
299	Cutting-Edge Brain Imaging with Positron Emission Tomography. <i>PET Clinics</i> , 2007, 2, 91-104.	1.5	3
300	Imaging the Neurochemistry of Alcohol and Substance Abuse. <i>Neuroimaging Clinics of North America</i> , 2007, 17, 539-555.	0.5	49
301	Applications of Clinical Dopamine Imaging. <i>PET Clinics</i> , 2007, 2, 45-65.	1.5	0
302	Effect of acetylcholinesterase inhibitors on the binding of nicotinic $\alpha 4 \beta 2$ receptor PET radiotracer, 18F-nifene: A measure of acetylcholine competition. <i>Synapse</i> , 2007, 61, 29-36.	0.6	28
303	Amphetamine-induced dopamine release: Duration of action as assessed with the D2/3 receptor agonist radiotracer ( $\alpha$ -[11C]propyl-norapomorphine ([11C]NPA) in an anesthetized nonhuman primate. <i>Synapse</i> , 2007, 61, 106-109.	0.6	30
304	Agonist-dependent internalization of D2 receptors: Imaging quantification by confocal microscopy. <i>Synapse</i> , 2007, 61, 231-241.	0.6	23
305	Effect on [11C]DASB binding after tranylcypromine-induced increase in serotonin concentration: Positron emission tomography studies in monkeys and rats. <i>Synapse</i> , 2007, 61, 440-449.	0.6	23
306	Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. <i>Synapse</i> , 2007, 61, 523-530.	0.6	61
307	Time-course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. <i>Synapse</i> , 2007, 61, 707-714.	0.6	59
308	The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. <i>Synapse</i> , 2007, 61, 637-645.	0.6	87
309	Measurement of Methylphenidate-Induced Change in Extrastriatal Dopamine Concentration using [11C]FLB 457 PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 369-377.	2.4	79
310	Positron Emission Tomography Displacement Sensitivity: Predicting Binding Potential Change for Positron Emission Tomography Tracers Based on Their Kinetic Characteristics. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 606-617.	2.4	46
311	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1533-1539.	2.4	1,840
312	Fibromyalgia patients show an abnormal dopamine response to pain. <i>European Journal of Neuroscience</i> , 2007, 25, 3576-3582.	1.2	362
313	Assessment of $\beta 1$ -adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 394-403.	1.1	4
314	Extrastriatal D2 and striatal D2 receptors in depressive illness: Pilot PET studies using [11C]FLB 457 and [11C]raclopride. <i>Journal of Affective Disorders</i> , 2007, 101, 113-122.	2.0	48
315	Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography. <i>European Journal of Pharmacology</i> , 2007, 564, 75-79.	1.7	7
316	Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 87, 426-433.	1.3	84

#	ARTICLE	IF	CITATIONS
317	Cerebral Autoregulation and Syncope. <i>Progress in Cardiovascular Diseases</i> , 2007, 50, 49-80.	1.6	70
318	Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 69-74.	0.9	48
319	Acute prefrontal rTMS increases striatal dopamine to a similar degree as d-amphetamine. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 251-255.	0.9	103
320	Cocaine sensitization and dopamine mediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction. <i>Psychopharmacology</i> , 2007, 191, 705-717.	1.5	68
321	Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders. <i>Molecular Imaging and Biology</i> , 2007, 9, 243-257.	1.3	64
322	Voxel-based NK1 Receptor Occupancy Measurements with [18F]SPA-RQ and Positron Emission Tomography: A Procedure for Assessing Errors from Image Reconstruction and Physiological Modeling. <i>Molecular Imaging and Biology</i> , 2007, 9, 284-294.	1.3	5
323	Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. <i>Journal of Neural Transmission</i> , 2007, 114, 1433-1442.	1.4	19
325	Dopamine hypothesis of schizophrenia: Making sense of it all. <i>Current Psychiatry Reports</i> , 2007, 9, 329-336.	2.1	191
326	Initial Comparison of ntPET with Microdialysis Measurements of Methamphetamine-Induced Dopamine Release in Rats: Support for Estimation of Dopamine Curves from PET Data. <i>Molecular Imaging and Biology</i> , 2008, 10, 67-73.	1.3	21
327	Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. <i>Psychopharmacology</i> , 2008, 197, 581-590.	1.5	61
328	Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. <i>Psychopharmacology</i> , 2008, 200, 487-496.	1.5	40
329	Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1109-1116.	3.3	8
330	Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1147-1158.	3.3	18
332	Test of retest variability and reliability of <sup>123</sup> I-BZM SPECT measurement of striatal dopamine D <sub>2</sub> receptor availability in healthy volunteers and influence of iterative reconstruction algorithms. <i>Synapse</i> , 2008, 62, 62-69.	0.6	20
333	Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in vivo <sup>11</sup> C PET imaging ([ <sup>11</sup> C] raclopride) and in vitro ([ <sup>3</sup> H] spiperone) autoradiography. <i>Synapse</i> , 2008, 62, 50-61.	0.6	128
334	Small effect of dopamine release and no effect of dopamine depletion on [ <sup>18</sup> F]fallypride binding in healthy humans. <i>Synapse</i> , 2008, 62, 399-408.	0.6	104
335	Occupancy of dopamine D <sub>2/3</sub> receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [ <sup>11</sup> C]MNPA. <i>Synapse</i> , 2008, 62, 756-763.	0.6	28
336	Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature. <i>Synapse</i> , 2008, 62, 851-869.	0.6	81

#	ARTICLE	IF	CITATIONS
337	Synthesis and evaluation of [ <i>O</i> -methyl- <sup>11</sup> C]-3-(4-(2-methoxyphenyl)-piperazin-1-yl)propoxy-4-azatricyclo[5.2.1.0 <sup>2,6</sup> ]decan-8-one as a 5-HT <sub>1A</sub> receptor agonist PET ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 132-136.		
338	Synthesis of <sup>11</sup> C, <sup>18</sup> F, <sup>15</sup> O, and <sup>13</sup> N Radiolabels for Positron Emission Tomography. Angewandte Chemie - International Edition, 2008, 47, 8998-9033.	7.2	805
340	Nonhuman Primate Neuroimaging and the Neurobiology of Psychostimulant Addiction. Annals of the New York Academy of Sciences, 2008, 1141, 176-194.	1.8	29
341	In Vivo Imaging of Neurotransmission and Brain Receptors in Dementia. Journal of Neuroimaging, 2008, 18, 111-124.	1.0	22
342	Addiction: the clinical interface. British Journal of Pharmacology, 2008, 154, 397-405.	2.7	39
343	Theta burst stimulation-induced inhibition of dorsolateral prefrontal cortex reveals hemispheric asymmetry in striatal dopamine release during a set-shifting task - a TMS-[ <sup>11</sup> C]raclopride PET study. European Journal of Neuroscience, 2008, 28, 2147-2155.	1.2	166
344	Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology, 2008, 75, 196-217.	2.0	189
345	Fluorine magnetic resonance in vivo: A powerful tool in the study of drug distribution and metabolism. Drug Discovery Today, 2008, 13, 473-480.	3.2	56
346	Greater availability of dopamine transporters in patients with major depression - A dual-isotope SPECT study. Psychiatry Research - Neuroimaging, 2008, 162, 230-235.	0.9	60
347	Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naïve schizophrenic patients. Schizophrenia Research, 2008, 101, 133-141.	1.1	43
348	Small Molecule Receptors as Imaging Targets. Handbook of Experimental Pharmacology, 2008, , 93-129.	0.9	8
349	Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Progress in Brain Research, 2008, 172, 495-513.	0.9	64
350	Molecular Imaging II. Handbook of Experimental Pharmacology, 2008, , .	0.9	2
351	What were they thinking?. Neuroscience Letters, 2008, 430, 38-42.	1.0	21
352	Levodopa increases memory encoding and dopamine release in the striatum in the elderly. Neurobiology of Aging, 2008, 29, 267-279.	1.5	80
353	Decreased dopamine transporter availability in male smokers - A dual isotope SPECT study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 274-279.	2.5	73
354	Positron emission tomography ligand activation studies in the sports sciences: Measuring neurochemistry in vivo. Methods, 2008, 45, 307-318.	1.9	36
355	The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models and Perspectives for Their Improvement. , 2008, , 1-57.		8

#	ARTICLE	IF	CITATIONS
356	Applying Neuroimaging Ligands to Study Major Depressive Disorder. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 287-304.	2.5	52
357	Striatal dopamine transmission in healthy humans during a passive monetary reward task. <i>NeuroImage</i> , 2008, 39, 2058-2065.	2.1	37
358	Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. <i>NeuroImage</i> , 2008, 40, 1287-1295.	2.1	65
359	In vivo quantification of 5-HT1A [18F]MPPF interactions in rats using the YAP-(S)PET scanner and a $^{125}$ I-microprobe. <i>NeuroImage</i> , 2008, 41, 823-834.	2.1	16
360	Imaging dopamine release with Positron Emission Tomography (PET) and 11C-raclopride in freely moving animals. <i>NeuroImage</i> , 2008, 41, 1051-1066.	2.1	55
361	In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. <i>NeuroImage</i> , 2008, 42, 306-314.	2.1	178
362	Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. <i>European Neuropsychopharmacology</i> , 2008, 18, 262-270.	0.3	92
363	The Runner's High: Opioidergic Mechanisms in the Human Brain. <i>Cerebral Cortex</i> , 2008, 18, 2523-2531.	1.6	362
365	Reduced striatal D <sub>1</sub> receptor binding in autosomal dominant nocturnal frontal lobe epilepsy. <i>Neurology</i> , 2008, 71, 795-798.	1.5	60
366	Brain Imaging in Nonhuman Primates: Insights into Drug Addiction. <i>ILAR Journal</i> , 2008, 49, 89-102.	1.8	24
367	First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2008, 33, 279-289.	2.8	109
369	Age-related diurnal effect on D2 receptor binding: a preliminary PET study. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 671-8.	1.0	12
370	Chapter 4 Functional neuroimaging of cognition. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 88, 61-111.	1.0	14
371	Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. <i>Journal of Psychopharmacology</i> , 2008, 22, 882-894.	2.0	29
372	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , 2008, 193, 65-72.	1.7	64
373	Evaluation of the automatic three-dimensional delineation of caudate and putamen for PET receptor occupancy studies. <i>Nuclear Medicine Communications</i> , 2008, 29, 53-65.	0.5	8
374	Postpartum Depression. , 2008, , 175-199.		6
376	Mechanisms of Action of Deep Brain Stimulation. , 2009, , 157-169.		10

#	ARTICLE	IF	CITATIONS
377	Monoamines: Release Studies. , 2009, , 953-960.		0
378	Lower Level of Endogenous Dopamine in Patients With Cocaine Dependence: Findings From PET Imaging of D <sub>2</sub> /D <sub>3</sub> Receptors Following Acute Dopamine Depletion. American Journal of Psychiatry, 2009, 166, 1170-1177.	4.0	148
379	Cortical Dopamine in Schizophrenia. , 2009, , 1-16.		0
380	Δ <sup>9</sup> -Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology, 2009, 34, 759-766.	2.8	341
381	Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition. Current Neuropharmacology, 2009, 7, 195-206.	1.4	49
382	How have developments in molecular imaging techniques furthered schizophrenia research?. Imaging in Medicine, 2009, 1, 135-153.	0.0	9
383	Abstinence from Chronic Cocaine Self-Administration Alters Striatal Dopamine Systems in Rhesus Monkeys. Neuropsychopharmacology, 2009, 34, 1162-1171.	2.8	57
384	Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys. Neuropsychopharmacology, 2009, 34, 548-554.	2.8	91
385	Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects. Neuropsychopharmacology, 2009, 34, 624-633.	2.8	70
386	Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology, 2009, 72, 528-534.	1.5	79
387	Target site occupancy: Emerging generalizations from clinical and preclinical studies. , 2009, 122, 281-301.		124
388	Increase of striatal dopamine transmission in first episode drug-naïve schizophrenic patients as demonstrated by [123I]IBZM SPECT. Psychiatry Research - Neuroimaging, 2009, 173, 183-189.	0.9	23
389	The effects of lorazepam on extrastriatal dopamine D2/3-receptors – A double-blind randomized placebo-controlled PET study. Psychiatry Research - Neuroimaging, 2009, 174, 130-137.	0.9	9
390	Radiolabelling with short-lived PET (positron emission tomography) isotopes using microfluidic reactors. Journal of Chemical Technology and Biotechnology, 2009, 84, 309-315.	1.6	53
391	Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on <i>in vivo</i> D <sub>2</sub> receptor occupancy and behavioural conditioned avoidance response. Biopharmaceutics and Drug Disposition, 2009, 30, 209-220.	1.1	10
392	Positron emission tomographic measure of brain dopamine dependence to nicotine as a model of drugs of abuse. Psychopharmacology, 2009, 204, 149-153.	1.5	9
393	The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 475-483.	3.3	33
394	Dopamine D <sub>2/3</sub> receptor occupancy of apomorphine in the nonhuman primate brain – A comparative PET study with [ <sup>11</sup> C]raclopride and [ <sup>11</sup> C]MNPA. Synapse, 2009, 63, 378-389.	0.6	33


#	ARTICLE	IF	CITATIONS
395	Pharmacological characterization of 2- <i>N</i> -propylnorapomorphine's interactions with D <sub>2</sub> and D <sub>3</sub> dopamine receptors. <i>Synapse</i> , 2009, 63, 462-475.	0.6	34
396	Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D <sub>2/3</sub> radiotracers [ <sup>11</sup> C]FLB 457 and [ <sup>11</sup> C]fallypride. <i>Synapse</i> , 2009, 63, 447-461.	0.6	127
397	Ketamine/xylazine anesthesia alters [ <sup>11</sup> C]MNPA binding to dopamine D <sub>2</sub> receptors and response to methamphetamine challenge in monkey brain. <i>Synapse</i> , 2009, 63, 534-537.	0.6	22
398	Ex vivo [ <sup>11</sup> C]α(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D <sub>2</sub> receptor in vitro. <i>Synapse</i> , 2009, 63, 998-1009.	0.6	23
399	C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. <i>Synapse</i> , 2009, 63, 907-912.	0.6	156
400	Dopamine Release in the Human Striatum: Motor and Cognitive Tasks Revisited. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 554-564.	2.4	42
401	Stress, alcohol and drug interaction: an update of human research. <i>Addiction Biology</i> , 2009, 14, 43-64.	1.4	203
402	When What You See Isn't What You Get: Alcohol Cues, Alcohol Administration, Prediction Error, and Human Striatal Dopamine. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 139-149.	1.4	60
403	The dopaminergic basis of human behaviors: A review of molecular imaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2009, 33, 1109-1132.	2.9	150
404	PET measurement of changes in D2/D3 dopamine receptor binding in a nonhuman primate during chronic deep brain stimulation of the bed nucleus of the stria terminalis. <i>Journal of Neuroscience Methods</i> , 2009, 176, 129-135.	1.3	10
405	Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate. <i>Behavioural Brain Research</i> , 2009, 204, 352-362.	1.2	59
406	In vivo imaging of synaptic function in the central nervous system. <i>Behavioural Brain Research</i> , 2009, 204, 1-31.	1.2	118
407	Behavioral and neurobiological characteristics influencing social hierarchy formation in female cynomolgus monkeys. <i>Neuroscience</i> , 2009, 158, 1257-1265.	1.1	44
408	C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 630-636.	2.5	106
409	Social support and striatal dopaminergic activities: Is there a connection?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1141-1146.	2.5	19
410	The Dopamine Hypothesis of Schizophrenia: Version III–The Final Common Pathway. <i>Schizophrenia Bulletin</i> , 2009, 35, 549-562.	2.3	2,149
411	Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects. <i>Biological Psychiatry</i> , 2009, 65, 1091-1093.	0.7	187
412	Molecular tools for assessing human depression by positron emission tomography. <i>European Neuropsychopharmacology</i> , 2009, 19, 611-628.	0.3	32

#	ARTICLE	IF	CITATIONS
413	Evidence for endogenous opioid release in the amygdala during positive emotion. <i>NeuroImage</i> , 2009, 44, 252-256.	2.1	70
414	Modulation of striatal dopamine D1 binding by cognitive processing. <i>NeuroImage</i> , 2009, 48, 398-404.	2.1	32
415	Dopaminergic function and progression of Parkinson's disease: PET findings. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S38-S40.	1.1	19
416	Nicotine- and methamphetamine-induced dopamine release evaluated with in-vivo binding of radiolabelled raclopride to dopamine D2 receptors: comparison with in-vivo microdialysis data. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 833.	1.0	9
417	Alcohol Craving and Relapse Prediction. <i>Frontiers in Neuroscience</i> , 2010, , 99-135.	0.0	16
418	Radiosynthesis and Evaluation of <sup>11</sup> C-CIMBI-5 as a 5-HT <sub>2A</sub> Receptor Agonist Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1763-1770.	2.8	48
419	COMT Val158Met Genotype Does Not Alter Cortical or Striatal Dopamine D2 Receptor Availability In Vivo. <i>Molecular Imaging and Biology</i> , 2010, 12, 192-197.	1.3	30
421	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.	2.8	92
422	Linking cognitive aging to alterations in dopamine neurotransmitter functioning: Recent data and future avenues. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 670-677.	2.9	339
423	MDMA-evoked changes in the binding of dopamine D <sub>2</sub> receptor ligands in striatum of rats with unilateral serotonin depletion. <i>Synapse</i> , 2010, 64, 70-82.	0.6	5
424	Further evaluation of the carbon-11 labeled D <sub>2/3</sub> agonist PET radiotracer PHNO: Reproducibility in tracer characteristics and characterization of extrastriatal binding. <i>Synapse</i> , 2010, 64, 301-312.	0.6	20
425	Endogenous competition against binding of [ <sup>18</sup> F]DMFP and [ <sup>18</sup> F]fallypride to dopamine D <sub>2/3</sub> receptors in brain of living mouse. <i>Synapse</i> , 2010, 64, 313-322.	0.6	44
426	Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[ <sup>11</sup> C]DTBZ study in humans. <i>Synapse</i> , 2010, 64, 417-420.	0.6	19
427	Fenfluramine-induced serotonin release decreases [ <sup>11</sup> C]AZ10419369 binding to 5-HT <sub>1B</sub> receptors in the primate brain. <i>Synapse</i> , 2010, 64, 573-577.	0.6	56
428	No effect of dopamine depletion on the binding of the high-affinity D <sub>2/3</sub> radiotracer [ <sup>11</sup> C]FLB 457 in the human cortex. <i>Synapse</i> , 2010, 64, 879-885.	0.6	14
429	Long-term cognitive enrichment affects opioid receptor expression in the amygdala of domestic pigs. <i>Genes, Brain and Behavior</i> , 2010, 9, 75-83.	1.1	30
430	Neuroimaging, Gut Peptides and Obesity: Novel Studies of the Neurobiology of Appetite. <i>Journal of Neuroendocrinology</i> , 2010, 22, 833-845.	1.2	50
431	Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1682-1706.	2.4	132



#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

432



#	ARTICLE	IF	CITATIONS
450	Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. <i>NeuroImage</i> , 2010, 52, 1521-1527.	2.1	72
451	Agonist binding fraction of dopamine D2/3 receptors in rat brain: A quantitative autoradiographic study. <i>Neurochemistry International</i> , 2010, 56, 747-752.	1.9	13
452	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 373-388.	1.8	20
453	Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. <i>NeuroImage</i> , 2010, 50, 260-266.	2.1	29
454	Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability. <i>NeuroImage</i> , 2010, 50, 323-328.	2.1	44
455	Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: Comparison to 11C-Raclopride PET. <i>NeuroImage</i> , 2010, 50, 1511-1518.	2.1	12
456	Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers. <i>Neuropsychopharmacology</i> , 2010, 35, 806-817.	2.8	71
457	Dopamine D2 Receptors as Treatment Targets in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 4, 56-73.	1.4	165
458	Behavioral Neurobiology of Schizophrenia and Its Treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2010, , .	0.8	8
459	Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D <sub>2</sub> Receptors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 189-194.	1.3	14
460	Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge. <i>Biological Psychiatry</i> , 2011, 69, 822-824.	0.7	67
461	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2011, 70, 770-776.	0.7	34
462	Advances in biomathematical modeling for PET neuroreceptor imaging. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e45-e51.	4.0	7
463	5-HT and depression: is the glass half-full?. <i>Current Opinion in Pharmacology</i> , 2011, 11, 45-51.	1.7	87
464	Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011, 1808, 1380-1399.	1.4	361
465	Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. <i>Neurochemistry International</i> , 2011, 58, 243-247.	1.9	14
466	Imaging biomarkers in Parkinson's disease. <i>Progress in Neurobiology</i> , 2011, 95, 614-628.	2.8	151
467	Sunshine-exposure variation of human striatal dopamine D2/D3 receptor availability in healthy volunteers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 107-110.	2.5	33

#	ARTICLE	IF	CITATIONS
468	In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. <i>Nuclear Medicine and Biology</i> , 2011, 38, 273-277.	0.3	23
469	All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 118-132.	1.9	185
470	Dysfunctional Brain Networks and Genetic Risk for Schizophrenia: Specific Neurotransmitter Systems. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 89-96.	1.9	28
471	Presynaptic Dopamine in Schizophrenia. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 104-109.	1.9	47
472	PET Applications in Animal Models of Neurodegenerative and Neuroinflammatory Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 11, 45-64.	0.8	3
473	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. <i>European Neuropsychopharmacology</i> , 2011, 21, 861-866.	0.3	17
474	Manganese and Parkinson's disease: a critical review and new findings. <i>Ciencia E Saude Coletiva</i> , 2011, 16, 4519-4566.	0.1	26
475	Analysis of Variance in Neuroreceptor Ligand Imaging Studies. <i>PLoS ONE</i> , 2011, 6, e23298.	1.1	3
476	Neurotransmitter Imaging: Basic Concepts and Future Perspectives. <i>Current Medical Imaging</i> , 2011, 7, 98-103.	0.4	19
477	Editorial [Hot topic: Neurotransmitter Imaging: Current Status and Challenges (Guest Editors:)] Tj ETQq1 1 0.784314 rgBT /Overlock 10 0,45	0.4	5
478	Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph. <i>Nature Methods</i> , 2011, 8, 347-352.	9.0	120
479	Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. <i>Nature Neuroscience</i> , 2011, 14, 257-262.	7.1	1,149
480	Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 293-304.	2.4	21
481	Dopaminergic mechanisms of target detection "P300 event related potential and striatal dopamine. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 212-218.	0.9	52
482	Increased in vivo [11C]raclopride binding to brain dopamine receptors in amphetamine-treated rats. <i>European Journal of Pharmacology</i> , 2011, 654, 254-257.	1.7	9
483	Isoflurane Anaesthesia Differentially Affects the Amphetamine Sensitivity of Agonist and Antagonist D2/D3 Positron Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine Release. <i>Molecular Imaging and Biology</i> , 2011, 13, 737-746.	1.3	26
484	Relationship Between Striatal Dopamine Transporter Availability and Sleep Quality in Healthy Adults. <i>Molecular Imaging and Biology</i> , 2011, 13, 1267-1271.	1.3	14
485	Neuroimaging and drug taking in primates. <i>Psychopharmacology</i> , 2011, 216, 153-171.	1.5	30

#	ARTICLE	IF	CITATIONS
486	Cortical and Sub-Cortical Effects in Primate Models of Cocaine Use: Implications for Addiction and the Increased Risk of Psychiatric Illness. <i>Neurotoxicity Research</i> , 2011, 19, 235-242.	1.3	11
487	Neuroimaging in Parkinson's Disease. <i>Neurotherapeutics</i> , 2011, 8, 72-81.	2.1	59
488	Differential effects of stress on [ <sup>11</sup> C]raclopride and [ <sup>11</sup> C]MNPA binding to striatal D <sub>2</sub> /D <sub>3</sub> dopamine receptors: A PET study in conscious monkeys. <i>Synapse</i> , 2011, 65, 84-89.	0.6	21
489	Test-retest variability of [ <sup>11</sup> C]raclopride binding potential in nontreatment-seeking alcoholics. <i>Synapse</i> , 2011, 65, 553-561.	0.6	22
490	Assessing the sensitivity of [ <sup>11</sup> C]p943, a novel 5-HT <sub>1B</sub> radioligand, to endogenous serotonin release. <i>Synapse</i> , 2011, 65, 1113-1117.	0.6	21
491	Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [ <sup>11</sup> C] P943: A positron emission tomography study in <i>Papio anubis</i> . <i>Synapse</i> , 2011, 65, 1119-1127.	0.6	28
492	Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [ <sup>11</sup> C]raclopride study in humans. <i>British Journal of Psychiatry</i> , 2011, 199, 391-397.	1.7	37
493	Cracking the Code: Dopamine Signaling in Cocaine Dependence. <i>American Journal of Psychiatry</i> , 2011, 168, 572-575.	4.0	0
494	Estrogen Shapes Dopamine-Dependent Cognitive Processes: Implications for Women's Health. <i>Journal of Neuroscience</i> , 2011, 31, 5286-5293.	1.7	304
495	Does intravenous <sup>11</sup> C-tetrahydrocannabinol increase dopamine release? A SPET study. <i>Journal of Psychopharmacology</i> , 2011, 25, 1462-1468.	2.0	84
496	Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D <sub>2/3</sub> receptors in major depressive disorder studied with [ <sup>11</sup> C]raclopride PET. <i>Journal of Psychopharmacology</i> , 2011, 25, 1329-1336.	2.0	33
497	Integrating PET with behavioral neuroscience using RatCAP tomography. <i>Reviews in the Neurosciences</i> , 2011, 22, 647-55.	1.4	22
498	Pharmacological challenge and synaptic response – assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). <i>Reviews in the Neurosciences</i> , 2011, 22, 625-45.	1.4	17
499	Imaging Dopamine Transmission in Cocaine Dependence: Link Between Neurochemistry and Response to Treatment. <i>American Journal of Psychiatry</i> , 2011, 168, 634-641.	4.0	188
500	Nonhuman Primate Positron Emission Tomography Neuroimaging in Drug Abuse Research. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 324-334.	1.3	26
501	Imaging of Seasonal Affective Disorder and Seasonality Effects on Serotonin and Dopamine Function in the Human Brain. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 11, 149-167.	0.8	22
502	Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates. <i>Neuropsychopharmacology</i> , 2011, 36, 511-518.	2.8	50
503	Brainstem changes in 5-HT <sub>1A</sub> receptor availability during migraine attack. <i>Cephalalgia</i> , 2011, 31, 84-94.	1.8	49

#	ARTICLE	IF	CITATIONS
504	Within-Subject Comparison of [ <sup>11</sup> C]-(+)-PHNO and [ <sup>11</sup> C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 127-136.	2.4	150
505	Extrasynaptic Neurotransmission in the Modulation of Brain Function. Focus on the Striatal Neuronal-Glial Networks. <i>Frontiers in Physiology</i> , 2012, 3, 136.	1.3	67
506	Confirmation of Fenfluramine Effect on 5-HT <sub>1B</sub> Receptor Binding of [ <sup>11</sup> C]AZ10419369 using an Equilibrium Approach. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 685-695.	2.4	34
507	Molecular Brain Imaging in the Multimodality Era. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1377-1392.	2.4	16
508	Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and Negative Symptoms. <i>Pharmacopsychiatry</i> , 2012, 45, S36-S41.	1.7	38
509	Postpartum and Depression Status are Associated With Lower [ <sup>11</sup> C]raclopride BPND in Reproductive-Age Women. <i>Neuropsychopharmacology</i> , 2012, 37, 1422-1432.	2.8	33
510	Radiotracers for SPECT imaging: current scenario and future prospects. <i>Radiochimica Acta</i> , 2012, 100, 95-107.	0.5	21
511	Neurochemical Imaging and Depressive Behaviours. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 14, 101-134.	0.8	10
512	Effects of Aerobic Exercise on Mood and Human Opioidergic Activation Measured by Positron Emission Tomography. , 2012, , 499-510.		1
513	Dopaminergic Neurotransmission in the Human Brain. <i>Neuroscientist</i> , 2012, 18, 149-168.	2.6	48
514	Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 1568-1579.	0.9	24
515	Applications of Imaging Biomarkers in the Early Clinical Development of Central Nervous System Therapeutic Agents. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 315-320.	2.3	11
516	Contributions of neuroimaging to understanding sex differences in cocaine abuse.. <i>Experimental and Clinical Psychopharmacology</i> , 2012, 20, 2-15.	1.3	28
517	Neurofunctional imaging of Î²-cell dynamics. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 91-100.	2.2	8
518	Neurobiology of Addiction. <i>Psychiatric Clinics of North America</i> , 2012, 35, 521-541.	0.7	30
519	Origins of delusions in Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 2274-2287.	2.9	48
520	Measuring Dopamine Synaptic Transmission with Molecular Imaging and Pharmacological Challenges: The State of the Art. <i>NeuroMethods</i> , 2012, , 163-203.	0.2	33
521	Influence of different cellular environments on [ <sup>3</sup> H]DASB radioligand binding. <i>Synapse</i> , 2012, 66, 1035-1039.	0.6	18

#	ARTICLE	IF	CITATIONS
522	Deficits in Dopamine D2 Receptors and Presynaptic Dopamine in Heroin Dependence: Commonalities and Differences with Other Types of Addiction. <i>Biological Psychiatry</i> , 2012, 71, 192-198.	0.7	136
523	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	0.7	222
524	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. <i>Biological Psychiatry</i> , 2012, 72, 371-377.	0.7	104
525	Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. <i>NeuroImage</i> , 2012, 59, 3922-3932.	2.1	30
526	A short-scan method for k3 estimation with moderately reversible PET ligands: Application of irreversible model to early-phase PET data. <i>NeuroImage</i> , 2012, 59, 3149-3158.	2.1	5
527	PET radiotracers for molecular imaging in the brain: Past, present and future. <i>NeuroImage</i> , 2012, 61, 363-370.	2.1	83
528	Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA. <i>NeuroImage</i> , 2012, 63, 423-433.	2.1	12
529	Neurochemical Imaging of Addictive Disorders. <i>NeuroMethods</i> , 2012, , 249-271.	0.2	2
530	Molecular Imaging of Mood Episodes. <i>NeuroMethods</i> , 2012, , 273-303.	0.2	0
531	Role of Dopamine D2 Receptors for Antipsychotic Activity. <i>Handbook of Experimental Pharmacology</i> , 2012, , 27-52.	0.9	106
532	The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course. <i>Handbook of Experimental Pharmacology</i> , 2012, , 1-26.	0.9	54
533	Functional Neuroimaging in Exercise and Sport Sciences. , 2012, , .		17
534	Molecular Imaging in the Clinical Neurosciences. <i>NeuroMethods</i> , 2012, , .	0.2	3
535	Striatal Dopamine Release and Genetic Variation of the Serotonin 2C Receptor in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 9344-9350.	1.7	41
536	Brain Imaging in Behavioral Neuroscience. <i>Current Topics in Behavioral Neurosciences</i> , 2012, , .	0.8	3
537	Molecular Imaging in Schizophrenia. <i>NeuroMethods</i> , 2012, , 305-321.	0.2	0
538	Brain Imaging in Addiction. , 2012, , 3-25.		1
539	Increased affinity of dopamine for D <sub>2</sub> versus D <sub>1</sub> receptors. Relevance for volume transmission in interpreting PET findings. <i>Synapse</i> , 2012, 66, 196-203.	0.6	53

#	ARTICLE	IF	CITATIONS
540	Compensation for cranial spillâ€n into the cerebellum improves quantitation of striatal dopamine D <sub>2/3</sub> receptors in rats with prolonged [ <sup>18</sup> F]â€MFP infusions. <i>Synapse</i> , 2012, 66, 705-713.	0.6	9
541	Neural and Behavioral Endophenotypes in ADHD. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 11, 65-91.	0.8	16
542	The Development, Past Achievements, and Future Directions of Brain PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1426-1454.	2.4	119
543	Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 337-372.	1.4	69
544	Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging. <i>Psychopharmacology</i> , 2012, 221, 67-77.	1.5	44
545	Amphetamine challenge decreases yohimbine binding to $\alpha_2$ adrenoceptors in Landrace pig brain. <i>Psychopharmacology</i> , 2012, 222, 155-163.	1.5	23
546	Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 183-191.	1.8	13
547	Serotonergic modulation of receptor occupancy in rats treated with $\alpha$ -DOPA after unilateral 6â€OHDA lesioning. <i>Journal of Neurochemistry</i> , 2012, 120, 806-817.	2.1	37
548	Automated preparation of the dopamine D2/3 receptor agonist ligand [ <sup>11</sup> C]-(+)-PHNO for human PET imaging studies. <i>Applied Radiation and Isotopes</i> , 2012, 70, 380-387.	0.7	9
549	Imaging the high-affinity state of the dopamine D2 receptor in vivo: Fact or fiction?. <i>Biochemical Pharmacology</i> , 2012, 83, 193-198.	2.0	59
550	Striatal dopamine in bulimia nervosa: A pet imaging study. <i>International Journal of Eating Disorders</i> , 2012, 45, 648-656.	2.1	71
551	Reliability of striatal [ <sup>11</sup> C]raclopride binding in smokers wearing transdermal nicotine patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 220-225.	3.3	8
552	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.	1.9	52
553	5â€HT radioligands for human brain imaging with PET and SPECT. <i>Medicinal Research Reviews</i> , 2013, 33, 54-111.	5.0	138
554	Introduction to the analysis of PET data in oncology. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 419-436.	0.8	5
556	Behavioral Neurobiology of Depression and Its Treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2013, , .	0.8	4
557	Striatal ups and downs: Their roles in vulnerability to addictions in humans. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1999-2014.	2.9	153
558	Schizophrenia and dopamine receptors. <i>European Neuropsychopharmacology</i> , 2013, 23, 999-1009.	0.3	93

#	ARTICLE	IF	CITATIONS
559	Are dopamine D2 receptors out of control in psychosis?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 146-152.	2.5	34
560	Synthesis and in vivo evaluation of [18F]2-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([18F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates. Bioorganic and Medicinal Chemistry. 2013. 21. 5598-5604.	1.4	23
561	Striatal dopaminergic dysfunction at rest and during task performance in writerâ€™s cramp. Brain, 2013, 136, 3645-3658.	3.7	61
562	Brain stimulation and functional imaging with fMRI and PET. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 77-95.	1.0	22
563	Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. European Neuropsychopharmacology, 2013, 23, 1423-1431.	0.3	133
564	Current status of positron emission tomography radiotracers for serotonin receptors in humans. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 105-113.	0.5	22
565	Dopamine and training-related working-memory improvement. Neuroscience and Biobehavioral Reviews, 2013, 37, 2209-2219.	2.9	76
566	Studies of the metabotropic glutamate receptor 5 radioligand [ <sup>11</sup> C]ABP688 with N-acetylcysteine challenge in rhesus monkeys. Synapse, 2013, 67, 489-501.	0.6	42
567	Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum. NeuroImage, 2013, 67, 1-6.	2.1	88
568	Speech-induced striatal dopamine release is left lateralized and coupled to functional striatal circuits in healthy humans: A combined PET, fMRI and DTI study. NeuroImage, 2013, 70, 21-32.	2.1	46
569	A receptor-based model for dopamine-induced fMRI signal. NeuroImage, 2013, 75, 46-57.	2.1	57
570	Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 178-183.	2.5	19
571	Neural interactions that give rise to musical pleasure.. Psychology of Aesthetics, Creativity, and the Arts, 2013, 7, 62-75.	1.0	56
572	DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. International Journal of Neuropsychopharmacology, 2013, 16, 2095-2101.	1.0	51
573	A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain, 2013, 136, 3252-3270.	3.7	90
574	Targeting Dopamine Receptors Subtype 2 (D2DR) in Pheochromocytomas: Head-to-Head Comparison Between In Vitro and In Vivo Findings. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1951-E1955.	1.8	6
575	Individual Differences in Frontal Cortical Thickness Correlate with the d-Amphetamine-Induced Striatal Dopamine Response in Humans. Journal of Neuroscience, 2013, 33, 15285-15294.	1.7	22
576	Striatal Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia: A Case-Control SPECT Study With [99mTc]-TRODAT-1 and a Meta-Analysis. Schizophrenia Bulletin, 2013, 39, 378-386.	2.3	38



#	ARTICLE	IF	CITATIONS
577	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. <i>Sleep</i> , 2013, 36, 51-57.	0.6	93
578	The dopamine D <sub>1</sub> receptor agonist ( <i>S</i> )-[ <sup>11</sup> C]-N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration-a positron emission tomography examination in the monkey brain. <i>Synapse</i> , 2013, 67, 586-595.	0.6	8
579	Feedback-Controlled Bolus plus Infusion (FC-B/I) Method for Quantitative Drug Assessment in Living Brain with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 85-90.	2.4	4
580	Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11169-11174.	3.3	112
581	Abnormal Striatal Dopaminergic Neurotransmission during Rest and Task Production in Spasmodic Dysphonia. <i>Journal of Neuroscience</i> , 2013, 33, 14705-14714.	1.7	75
582	Can Neuroscience Improve Addiction Treatment and Policies?. <i>Public Health Reviews</i> , 2013, 35, .	1.3	4
583	Brain structural, neurochemical and neuroinflammatory markers of psychosis onset and relapse. <i>International Clinical Psychopharmacology</i> , 2013, , 1.	0.9	16
584	Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1577-1586.	1.0	78
585	Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 23.	1.7	156
586	The Functional DRD3 Ser9Gly Polymorphism (rs6280) Is Pleiotropic, Affecting Reward as Well as Movement. <i>PLoS ONE</i> , 2013, 8, e54108.	1.1	60
587	Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [ <sup>11</sup> C]-(+)-PHNO PET Study. <i>PLoS ONE</i> , 2013, 8, e60382.	1.1	11
588	Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity. <i>Frontiers in Psychiatry</i> , 2013, 4, 8.	1.3	20
589	Kappa-Opioid Receptor Signaling in the Striatum as a Potential Modulator of Dopamine Transmission in Cocaine Dependence. <i>Frontiers in Psychiatry</i> , 2013, 4, 44.	1.3	25
590	Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e90759.	1.1	16
591	The Role of Rhythm in Speech and Language Rehabilitation: The SEP Hypothesis. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 777.	1.0	71
592	Imaging of Neurochemical Transmission in the Central Nervous System. , 2014, , 453-484.		0
593	Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology. <i>Current Molecular Imaging</i> , 2014, 3, 15-26.	0.7	0
594	Dopamine Receptor Imaging in Schizophrenia. , 2014, , 341-360.		2

#	ARTICLE	IF	CITATIONS
595	Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans using the Agonist Radiotracer [ <sup>11</sup> C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 2769-2776.	2.8	31
596	Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [ <sup>11</sup> C]FLB 457 PET study. <i>Molecular Psychiatry</i> , 2014, 19, 302-310.	4.1	47
597	Amphetamine-Induced Dopamine Release and Neurocognitive Function in Treatment-Naive Adults with ADHD. <i>Neuropsychopharmacology</i> , 2014, 39, 1498-1507.	2.8	38
598	Imaging Endogenous Opioid Peptide Release with [ <sup>11</sup> C]Carfentanil and [ <sup>3</sup> H]Diprenorphine: Influence of Agonist-Induced Internalization. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1604-1612.	2.4	29
599	Tracer Kinetic Models in PET. , 2014, , 229-252.		0
600	A Neural Population Model Incorporating Dopaminergic Neurotransmission during Complex Voluntary Behaviors. <i>PLoS Computational Biology</i> , 2014, 10, e1003924.	1.5	7
601	No correlation between serotonin and its metabolite 5-HIAA in the cerebrospinal fluid and [ <sup>11</sup> C]AZ10419369 binding measured with PET in healthy volunteers. <i>Synapse</i> , 2014, 68, 480-483.	0.6	6
603	A Decade of Studies on Manganese Neurotoxicity in Non-Human Primates: Novel Findings and Future Directions. <i>Issues in Toxicology</i> , 2014, , 459-476.	0.2	0
604	Probabilistic classification learning with corrective feedback is associated with in vivo striatal dopamine release in the ventral striatum, while learning without feedback is not. <i>Human Brain Mapping</i> , 2014, 35, 5106-5115.	1.9	23
605	Dopamine Receptors and Dopamine Release. , 2014, , 289-339.		1
606	Evaluating The Antidepressant Efficacy of Aripiprazole Using a Chronic Mild Stress Model: An Experimental Study. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 15-22.	0.9	2
607	Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. <i>EJNMMI Research</i> , 2014, 4, 53.	1.1	4
608	Investigating expectation and reward in human opioid addiction with [ <sup>11</sup> C]-raclopride PET. <i>Addiction Biology</i> , 2014, 19, 1032-1040.	1.4	24
609	Data collection and analysis strategies for phMRI. <i>Neuropharmacology</i> , 2014, 84, 65-78.	2.0	20
610	Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. <i>Neuropharmacology</i> , 2014, 76, 498-509.	2.0	135
611	1-Methyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Amine with Unexpected Mechanism of Action: New Vistas of Therapeutic Application. <i>Neurotoxicity Research</i> , 2014, 25, 1-12.	1.3	37
612	Effect of mazindol on extracellular dopamine concentration in human brain measured by PET. <i>Psychopharmacology</i> , 2014, 231, 2321-2325.	1.5	3
613	Connectivity-Based Functional Analysis of Dopamine Release in the Striatum Using Diffusion-Weighted MRI and Positron Emission Tomography. <i>Cerebral Cortex</i> , 2014, 24, 1165-1177.	1.6	276

#	ARTICLE	IF	CITATIONS
614	Dopamine receptor mapping with PET imaging in Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2251-2263.	1.8	45
615	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [11C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	2.8	54
616	Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. <i>Psychoneuroendocrinology</i> , 2014, 39, 74-87.	1.3	86
617	Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. <i>Neuropsychopharmacology</i> , 2014, 39, 866-874.	2.8	43
618	Amphetamine-induced release of dopamine in primate prefrontal cortex and striatum: striking differences in magnitude and timecourse. <i>Journal of Neurochemistry</i> , 2014, 130, 490-497.	2.1	28
621	Simultaneous fMRI-PET of the opioidergic pain system in human brain. <i>NeuroImage</i> , 2014, 102, 275-282.	2.1	59
622	Distinct regional age effects on [11C]AZ10419369 binding to 5-HT 1B receptors in the human brain. <i>NeuroImage</i> , 2014, 103, 303-308.	2.1	21
623	Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1055-1069.	1.0	29
624	Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study. <i>NeuroImage</i> , 2014, 102, 590-595.	2.1	37
625	Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors. <i>Drug and Alcohol Dependence</i> , 2014, 143, 29-35.	1.6	14
626	Reduced Dopamine Response to Amphetamine in Subjects at Ultra-High Risk for Addiction. <i>Biological Psychiatry</i> , 2014, 76, 23-30.	0.7	49
627	Advances in processes for PET radiotracer synthesis: Separation of [18F]fluoride from enriched [18O]water. <i>Applied Radiation and Isotopes</i> , 2014, 91, 64-70.	0.7	16
628	<sup>18</sup> F-MCL-524, an <sup>18</sup> F-Labeled Dopamine D <sub>2</sub> and D <sub>3</sub> Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1164-1170.	2.8	20
629	Dopamine release in nucleus accumbens during rewarded task switching measured by [11C]raclopride. <i>NeuroImage</i> , 2014, 99, 357-364.	2.1	34
630	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	2.8	86
631	Relationship between impulsivity, prefrontal anticipatory activation, and striatal dopamine release during rewarded task performance. <i>Psychiatry Research - Neuroimaging</i> , 2014, 223, 244-252.	0.9	49
632	The influence of different cellular environments on PET radioligand binding: An application to D2/3-dopamine receptor imaging. <i>Neuropharmacology</i> , 2014, 85, 305-313.	2.0	13
633	PET studies in nonhuman primate models of cocaine abuse: Translational research related to vulnerability and neuroadaptations. <i>Neuropharmacology</i> , 2014, 84, 138-151.	2.0	32

#	ARTICLE	IF	CITATIONS
636	How Imaging Glutamate, $^{13}\text{C}$ -Aminobutyric Acid, and Dopamine Can Inform the Clinical Treatment of Alcohol Dependence and Withdrawal. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2268-2282.	1.4	21
637	Optimising $^{18}\text{F}$ -PET approaches to measuring $^{5\text{HT}}$ release in human brain. <i>Synapse</i> , 2015, 69, 505-511.	0.6	15
638	Influence of agonist induced internalization on [ $^3\text{H}$ ]Ro154513 binding—an application to imaging fluctuations in endogenous GABA with positron emission tomography. <i>Synapse</i> , 2015, 69, 60-65.	0.6	10
639	[ $^{11}\text{C}$ ]Carbon monoxide in labeling chemistry and positron emission tomography tracer development: scope and limitations. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 86-98.	0.5	51
640	PIXSIC: A Wireless Intracerebral Radiosensitive Probe in Freely Moving Rats. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00020.	0.7	7
641	Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30144-30163.	1.8	55
642	Molecular and Functional Imaging of Internet Addiction. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	29
643	Reference Region Modeling Approaches for Amphetamine Challenge Studies with [ $^{11}\text{C}$ ]FLB 457 and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 623-629.	2.4	50
644	Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. <i>Biomarkers in Medicine</i> , 2015, 9, 277-297.	0.6	59
645	Amphetamine Decreases $^{125}\text{I}$ -Adrenoceptor Binding of [ $^{11}\text{C}$ ]ORM-13070: A PET Study in the Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu081-pyu081.	1.0	13
646	ELECTROCHEMICAL RECORDINGS DURING DEEP BRAIN STIMULATION IN ANIMALS AND HUMANS: WINCS, MINCS, AND CLOSED-LOOP DBS. , 2015, , 225-250.		0
647	The Correlation Between Mid-Brain Serotonin Transporter Availability and Intelligence Quotient in Healthy Volunteers. <i>European Psychiatry</i> , 2015, 30, 193-197.	0.1	6
648	Intravenous Ethanol Increases Dopamine Release in the Ventral Striatum in Humans: PET Study Using Bolus-Plus-Infusion Administration of [ $^{11}\text{C}$ ]raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 424-431.	2.4	36
649	Validation of [ $^{11}\text{C}$ ]ORM-13070 as a $^{18}\text{F}$ -PET tracer for $^{125}\text{I}$ -adrenoceptors in the human brain. <i>Synapse</i> , 2015, 69, 172-181.	0.6	14
650	Decreased $^{125}\text{I}$ -adrenoceptor binding in the Flinders Sensitive Line rat model of depression. <i>Neuropharmacology</i> , 2015, 91, 97-102.	2.0	22
651	Test-retest reliability of $^{11}\text{C}$ -ORM-13070 in PET imaging of $^{125}\text{I}$ -adrenoceptors in vivo in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 120-127.	3.3	130
652	Dopaminergic function and intertemporal choice. <i>Translational Psychiatry</i> , 2015, 5, e491-e491.	2.4	53
653	Measuring Cigarette Smoking-Induced Cortical Dopamine Release: A [ $^{11}\text{C}$ ]FLB-457 PET Study. <i>Neuropsychopharmacology</i> , 2015, 40, 1417-1427.	2.8	43

#	ARTICLE	IF	CITATIONS
654	Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. <i>Clinica Chimica Acta</i> , 2015, 449, 60-62.	0.5	29
655	The dopaminergic response to acute stress in health and psychopathology: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 56, 241-251.	2.9	55
656	Sensitivity of [11C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects. <i>Psychopharmacology</i> , 2015, 232, 4169-4178.	1.5	12
657	Functional neuroimaging of amphetamine-induced striatal neurotoxicity in the pleiotrophin knockout mouse model. <i>Neuroscience Letters</i> , 2015, 591, 132-137.	1.0	7
658	Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. <i>NeuroImage</i> , 2015, 112, 225-231.	2.1	56
659	Comparison of HRRT and HR+ Scanners for Quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil Brain Studies. <i>Molecular Imaging and Biology</i> , 2015, 17, 129-139.	1.3	13
660	Striatal D <sub>2/3</sub> Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. <i>Schizophrenia Bulletin</i> , 2015, 41, 1143-1152.	2.3	34
661	The Anatomy of Parkinsonian Disorders. , 2015, , 759-767.		0
662	Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. <i>Neuropsychopharmacology</i> , 2015, 40, 2865-2872.	2.8	14
663	Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. <i>Psychopharmacology</i> , 2015, 232, 3443-3453.	1.5	55
664	Quantitative imaging of protein targets in the human brain with PET. <i>Physics in Medicine and Biology</i> , 2015, 60, R363-R411.	1.6	61
665	Long-Term Test-Retest Reliability of Striatal and Extrastriatal Dopamine D <sub>2/3</sub> Receptor Binding: Study with [ <sup>11</sup> C]Raclopride and High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1199-1205.	2.4	72
666	Determination of in Vivo Enzyme Occupancy Utilizing Inhibitor Dissociation Kinetics. <i>Journal of the American Chemical Society</i> , 2015, 137, 11230-11233.	6.6	3
667	Application of cross-species PET imaging to assess neurotransmitter release in brain. <i>Psychopharmacology</i> , 2015, 232, 4129-4157.	1.5	61
668	Central pharmacokinetics of levodopa: Lessons from imaging studies. <i>Movement Disorders</i> , 2015, 30, 73-79.	2.2	11
670	Functional imaging markers as outcome measures in clinical trials for Parkinson's disease. , 0, , 242-248.		0
671	The Reticular-Activating Hypofrontality (RAH) Model of Acute Exercise. , 2016, , 147-166.		13
672	Imaging Dopamine Alterations in Cannabis Dependence. , 2016, , 786-794.		0

#	ARTICLE	IF	CITATIONS
673	Relationship Between L-DOPA-Induced Reduction in Motor and Exploratory Activity and Striatal Dopamine D2 Receptor Binding in the Rat. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 352.	1.0	16
674	Chapter 17 Theories of Deep Brain Stimulation Mechanisms. , 2016, , 312-338.		0
675	Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys. <i>Neurobiology of Stress</i> , 2016, 3, 68-73.	1.9	7
676	Molecular fMRI. <i>Journal of Neuroscience</i> , 2016, 36, 4139-4148.	1.7	39
677	Molecular, Functional, and Structural Imaging of Major Depressive Disorder. <i>Neuroscience Bulletin</i> , 2016, 32, 273-285.	1.5	62
678	In Vivo Imaging of Dopamine Metabolism and Dopamine Transporter Function in the Human Brain. <i>Neuroinformatics</i> , 2016, , 203-220.	0.2	3
679	A regularized full reference tissue model for PET neuroreceptor mapping. <i>NeuroImage</i> , 2016, 139, 405-414.	2.1	9
680	Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition. <i>Translational Psychiatry</i> , 2016, 6, e911-e911.	2.4	58
681	Neurotransmitter Transporters. <i>Neuroinformatics</i> , 2016, , .	0.2	2
682	Imaging of cerebral $\alpha_4\beta_2$ nicotinic acetylcholine receptors with $^{18}\text{F}$ -[Flubatine] PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. <i>NeuroImage</i> , 2016, 141, 71-80.	2.1	48
683	Estimating the effect of endogenous dopamine on baseline [ $^{11}\text{C}$ ]-PHNO binding in the human brain. <i>Synapse</i> , 2016, 70, 453-460.	0.6	12
684	Molecular fMRI of Serotonin Transport. <i>Neuron</i> , 2016, 92, 754-765.	3.8	37
685	Catecholamines and cognition after traumatic brain injury. <i>Brain</i> , 2016, 139, 2345-2371.	3.7	73
686	DAT versus D2 receptor binding in the rat striatum: L-DOPA-induced motor activity is better predicted by reuptake than release of dopamine. <i>Synapse</i> , 2016, 70, 369-377.	0.6	5
687	PET Neurochemical Imaging Modes. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 20-27.	2.5	21
688	Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. <i>Neuropsychopharmacology</i> , 2016, 41, 1427-1436.	2.8	59
689	Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. <i>Translational Psychiatry</i> , 2016, 6, e747-e747.	2.4	86
690	MAOA-VNTR polymorphism modulates context-dependent dopamine release and aggressive behavior in males. <i>NeuroImage</i> , 2016, 125, 378-385.	2.1	48

#	ARTICLE	IF	CITATIONS
691	A perspective on the future role of brain pet imaging in exercise science. <i>NeuroImage</i> , 2016, 131, 73-80.	2.1	27
692	Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [ <sup>11</sup> C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2016, 41, 1513-1520.	2.8	18
693	Prefrontal cortex dopamine release measured in vivo with positron emission tomography: Implications for the stimulant paradigm. <i>NeuroImage</i> , 2016, 142, 663-667.	2.1	34
694	Family history of alcoholism is related to increased D <sub>2</sub> /D <sub>3</sub> receptor binding potential: a marker of resilience or risk?. <i>Addiction Biology</i> , 2017, 22, 218-228.	1.4	15
695	Cerebral 5-HT release correlates with [ <sup>11</sup> C]Cimbi36 PET measures of 5-HT <sub>2A</sub> receptor occupancy in the pig brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 425-434.	2.4	31
696	Pathway-Specific Dopamine Abnormalities in Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, 31-42.	0.7	221
697	Strategies for sensing neurotransmitters with responsive MRI contrast agents. <i>Chemical Society Reviews</i> , 2017, 46, 324-336.	18.7	38
698	GABAergic control of neostriatal dopamine D <sub>2</sub> receptor binding and behaviors in the rat. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 153, 76-87.	1.3	10
699	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.	2.2	88
700	Dopamine in the medial amygdala network mediates human bonding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2361-2366.	3.3	96
701	A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [ <sup>11</sup> C]-(+)-PHNO. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1112-1119.	1.4	7
702	Neurotransmitters behind pain relief with transcranial magnetic stimulation – positron emission tomography evidence for release of endogenous opioids. <i>European Journal of Pain</i> , 2017, 21, 1505-1515.	1.4	56
703	Striatal dopaminergic modulation of reinforcement learning predicts reward-oriented behavior in daily life. <i>Biological Psychology</i> , 2017, 127, 1-9.	1.1	60
704	Investigating the effects of norepinephrine $\alpha_1$ receptor blockade on dopamine levels: A pilot PET study with [ <sup>11</sup> C]-(+)-PHNO in controls. <i>Synapse</i> , 2017, 71, e21968.	0.6	2
705	Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study. <i>Translational Psychiatry</i> , 2017, 7, e1104-e1104.	2.4	14
706	A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 197-214.	1.1	15
707	Synthesis and Evaluation of a <sup>64</sup> Cu-Conjugate, a Selective $\mu$ -Opioid Receptor Positron Emission Tomography Imaging Agent. <i>Organic Letters</i> , 2017, 19, 2018-2021.	2.4	6
708	A single-scan protocol for absolute D <sub>2</sub> /3 receptor quantification with [ <sup>123</sup> I]IBZM SPECT. <i>NeuroImage</i> , 2017, 147, 461-472.	2.1	11

#	ARTICLE	IF	CITATIONS
709	Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 54-63.	2.5	15
710	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017, 16, 455-460.	1.4	33
711	Positron emission tomography (PET) imaging of nicotine-induced dopamine release in squirrel monkeys using [18F]Fallypride. <i>Drug and Alcohol Dependence</i> , 2017, 179, 254-259.	1.6	4
712	New Trends and Current Status of Positron-Emission Tomography and Single-Photon-Emission Computerized Tomography Radioligands for Neuronal Serotonin Receptors and Serotonin Transporter. <i>Bioconjugate Chemistry</i> , 2017, 28, 2647-2672.	1.8	21
713	Increased dopamine release after working-memory updating training: Neurochemical correlates of transfer. <i>Scientific Reports</i> , 2017, 7, 7160.	1.6	20
714	Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. <i>International Review of Psychiatry</i> , 2017, 29, 555-566.	1.4	6
715	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017, 1670, 220-234.	1.1	38
716	Imaging in Central Nervous System Drug Discovery. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 89-98.	2.5	38
717	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 235-240.	2.2	18
718	Blunted Dopamine Transmission in Addiction: Potential Mechanisms and Implications for Behavior. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 64-74.	2.5	35
719	Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol. <i>Psychopharmacology</i> , 2017, 234, 323-328.	1.5	7
720	Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, 43-51.	0.7	64
721	Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT <sub>2A</sub> Receptor in the Nonhuman Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 683-691.	1.0	25
722	News and views on in-vivo imaging of neurotransmission using PET and MRI. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 414-428.	0.4	20
723	Is there a relation between novelty seeking, striatal dopamine release and frontal cortical thickness?. <i>PLoS ONE</i> , 2017, 12, e0174219.	1.1	16
724	Sexual dimorphism in striatal dopaminergic responses promotes monogamy in social songbirds. <i>ELife</i> , 2017, 6, .	2.8	20
725	Cerebral serotonin release correlates with [ <sup>11</sup> C]AZ10419369 PET measures of 5-HT <sub>1B</sub> receptor binding in the pig brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1243-1252.	2.4	13
726	Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account. <i>Biological Psychiatry</i> , 2018, 84, 332-344.	0.7	87



#	ARTICLE	IF	CITATIONS
727	Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 591-598.	1.1	16
728	Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. <i>Biological Psychiatry</i> , 2018, 83, 707-714.	0.7	24
729	Update on Molecular Imaging in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2018, 34, 330-340.	1.5	19
730	Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2018, 272, 65-70.	0.9	6
731	Dual-radiotracer translational SPECT neuroimaging. Comparison of three methods for the simultaneous brain imaging of D2/3 and 5-HT2A receptors. <i>NeuroImage</i> , 2018, 176, 528-540.	2.1	4
732	PET imaging of dopamine-D2 receptor internalization in schizophrenia. <i>Molecular Psychiatry</i> , 2018, 23, 1506-1511.	4.1	24
733	Increased Striatal Dopamine Synthesis Capacity in Gambling Addiction. <i>Biological Psychiatry</i> , 2018, 83, 1036-1043.	0.7	97
734	Latent-Profile Analysis Reveals Behavioral and Brain Correlates of Dopamine-Cognition Associations. <i>Cerebral Cortex</i> , 2018, 28, 3894-3907.	1.6	34
735	The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. <i>Molecular Psychiatry</i> , 2018, 23, 59-69.	4.1	165
736	Mechanisms of Action of Deep Brain Stimulation. , 2018, , 193-210.		2
737	Lower dopamine tone in the striatum is associated with higher body mass index. <i>European Neuropsychopharmacology</i> , 2018, 28, 719-731.	0.3	25
738	Serotonin concentration enhancers at clinically relevant doses reduce [ <sup>11</sup> C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain. <i>Translational Psychiatry</i> , 2018, 8, 132.	2.4	11
739	Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies. <i>Frontiers in Psychiatry</i> , 2018, 9, 228.	1.3	20
740	Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. <i>Movement Disorders</i> , 2018, 33, 909-919.	2.2	89
741	Dopaminergic and serotonergic mechanisms in the modulation of pain: In vivo studies in human brain. <i>European Journal of Pharmacology</i> , 2018, 834, 337-345.	1.7	44
742	GABAergic Control of Nigrostriatal and Mesolimbic Dopamine in the Rat Brain. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 38.	1.0	15
743	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018, 14, 1522-1552.	0.4	68
744	Aerobic exercise modulates anticipatory reward processing via the $\mu$ -opioid receptor system. <i>Human Brain Mapping</i> , 2018, 39, 3972-3983.	1.9	24

#	ARTICLE	IF	CITATIONS
745	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 670-679.	2.3	39
746	Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting <i>N</i> -Methyl-D-aspartate (NMDA), L-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 403-419.	2.9	37
747	In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 352-364.	0.9	5
748	Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans. <i>Translational Psychiatry</i> , 2019, 9, 134.	2.4	40
749	Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. <i>Neuropsychopharmacology</i> , 2019, 44, 2205-2211.	2.8	27
750	Higher striatal D2-receptor availability in aerobically fit older adults but non-selective intervention effects after aerobic versus resistance training. <i>NeuroImage</i> , 2019, 202, 116044.	2.1	15
751	PET Occupancy and Competition in Translational Medicine and CNS Drug Development. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 159-172.	0.7	1
752	Disrupted Schizophrenia 1 functional polymorphisms and D2/D3 receptor availability: A [11C]PHNO imaging study. <i>Genes, Brain and Behavior</i> , 2019, 18, e12596.	1.1	0
753	An integrative framework for perceptual disturbances in psychosis. <i>Nature Reviews Neuroscience</i> , 2019, 20, 763-778.	4.9	53
754	Time-dependent assessment of stimulus-evoked regional dopamine release. <i>Nature Communications</i> , 2019, 10, 336.	5.8	31
755	Human Positron Emission Tomography Neuroimaging. <i>Annual Review of Biomedical Engineering</i> , 2019, 21, 551-581.	5.7	48
756	Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. <i>Neuropsychopharmacology</i> , 2019, 44, 1720-1727.	2.8	36
757	A role for foregut tyrosine metabolism in glucose tolerance. <i>Molecular Metabolism</i> , 2019, 23, 37-50.	3.0	29
758	Neuroimaging reward, craving, learning, and cognitive control in substance use disorders: review and implications for treatment. <i>British Journal of Radiology</i> , 2019, 92, 20180942.	1.0	29
759	Development of a non-human primate model to support CNS translational research: Demonstration with D-amphetamine exposure and dopamine response. <i>Journal of Neuroscience Methods</i> , 2019, 317, 71-81.	1.3	1
760	PET imaging of dopamine release in the frontal cortex of manganese-exposed non-human primates. <i>Journal of Neurochemistry</i> , 2019, 150, 188-201.	2.1	9
761	Synthesis, Crystal Structure, DFT Studies, Docking Studies, and Fluorescent Properties of 2-(Adamantan-1-yl)-2H-isoindole-1-carbonitrile. <i>Crystals</i> , 2019, 9, 24.	1.0	7
762	Neuroimaging in Parkinson Disease. , 0, , .		1

#	ARTICLE	IF	CITATIONS
763	Maternal overnutrition during critical developmental periods leads to different health adversities in the offspring: relevance of obesity, addiction and schizophrenia. <i>Scientific Reports</i> , 2019, 9, 17322.	1.6	21
764	Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 255.	1.4	29
766	Differential effects of D-cycloserine and amantadine on motor behavior and D2/3 receptor binding in the nigrostriatal and mesolimbic system of the adult rat. <i>Scientific Reports</i> , 2019, 9, 16128.	1.6	3
767	Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. <i>ACS Chemical Neuroscience</i> , 2019, 10, 384-395.	1.7	22
768	Food Intake Recruits Orosensory and Post-ingestive Dopaminergic Circuits to Affect Eating Desire in Humans. <i>Cell Metabolism</i> , 2019, 29, 695-706.e4.	7.2	69
769	Neurochemical Imaging in Addiction. , 2019, , 1-20.		1
770	<i>C957T</i> -mediated Variation in Ligand Affinity Affects the Association between <sup>11</sup> C-raclopride Binding Potential and Cognition. <i>Journal of Cognitive Neuroscience</i> , 2019, 31, 314-325.	1.1	13
771	Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. <i>Medicinal Research Reviews</i> , 2019, 39, 1014-1052.	5.0	22
772	Radiotracers for imaging of Parkinson's disease. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 75-89.	2.6	24
773	Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 179, 156-170.	1.3	13
774	Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 141-164.	2.9	32
775	PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders. <i>Neuroscience Letters</i> , 2019, 691, 26-34.	1.0	23
776	Quantitative Rodent Brain Receptor Imaging. <i>Molecular Imaging and Biology</i> , 2020, 22, 223-244.	1.3	25
777	Addiction theory matters—Why there is no dependence on caffeine or antidepressant medication. <i>Addiction Biology</i> , 2020, 25, e12735.	1.4	30
778	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 451-489.	3.3	86
779	High long-term test-retest reliability for extrastriatal <sup>11</sup> C-raclopride binding in healthy older adults. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1859-1868.	2.4	15
780	Balance between Transmitter Availability and Dopamine D2 Receptors in Prefrontal Cortex Influences Memory Functioning. <i>Cerebral Cortex</i> , 2020, 30, 989-1000.	1.6	26
781	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810.	2.8	34

#	ARTICLE	IF	CITATIONS
782	Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2. <i>Frontiers in Neuroscience</i> , 2020, 14, 682.	1.4	6
783	In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study. <i>Molecular Psychiatry</i> , 2021, 26, 4958-4967.	4.1	25
784	Cognitive Aging: The Role of Neurotransmitter Systems. , 2020, , 82-100.		2
785	The study of noninvasive brain stimulation using molecular brain imaging: A systematic review. <i>NeuroImage</i> , 2020, 219, 117023.	2.1	18
786	Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. <i>Journal of Psychopharmacology</i> , 2020, 34, 1030-1042.	2.0	32
787	[ <sup>11</sup> C]raclopride positron emission tomography study of dopamine D <sub>2/3</sub> receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 263-269.	1.0	9
788	Molecular neuroimaging of the serotonergic system with Positron Emission Tomography. <i>Handbook of Behavioral Neuroscience</i> , 2020, 31, 175-194.	0.7	2
789	Type of Anaesthetic Influences [ <sup>11</sup> C]MDL100,907 Binding to 5HT <sub>2A</sub> Receptors in Porcine Brain. <i>Molecular Imaging and Biology</i> , 2020, 22, 797-804.	1.3	2
790	<sup>11</sup> C- and <sup>18</sup> F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future. <i>Biomedicines</i> , 2021, 9, 108.	1.4	11
791	Measuring amphetamine-induced dopamine release in humans: A comparative meta-analysis of [ <sup>11</sup> C]raclopride and [ <sup>11</sup> C]α(+)-PHNO studies. <i>Synapse</i> , 2021, 75, e22195.	0.6	9
792	Striatal dopamine D <sub>2/3</sub> receptors in medication-naïve schizophrenia: an [ <sup>123</sup> I] IBZM SPECT study. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	3
793	Structural, Functional, and Molecular Imaging of Autism Spectrum Disorder. <i>Neuroscience Bulletin</i> , 2021, 37, 1051-1071.	1.5	34
794	[ <sup>18</sup> F]F13640, a 5-HT <sub>1A</sub> Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. <i>Frontiers in Neuroscience</i> , 2021, 15, 622423.	1.4	5
795	Does sodium oxybate inhibit brain dopamine release in humans? An exploratory neuroimaging study. <i>Human Psychopharmacology</i> , 2021, 36, e2791.	0.7	2
796	Molecular Imaging of Neurodegenerative Parkinsonism. <i>PET Clinics</i> , 2021, 16, 261-272.	1.5	0
797	Evaluating a new generation of wearable high-density diffuse optical tomography technology via retinotopic mapping of the adult visual cortex. <i>Neurophotonics</i> , 2021, 8, 025002.	1.7	18
798	Dynamic alterations in the central glutamatergic status following food and glucose intake: <i>in vivo</i> multimodal assessments in humans and animal models. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2928-2943.	2.4	4
799	Central Insulin Modulates Dopamine Signaling in the Human Striatum. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2949-2961.	1.8	24

#	ARTICLE	IF	CITATIONS
800	Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders. , 2022, 229, 107937.		35
801	Positron emission tomographic imaging in drug discovery. Drug Discovery Today, 2022, 27, 280-291.	3.2	21
803	Serotonergic Modulation of Nigrostriatal and Mesolimbic Dopamine and Motor/Exploratory Behaviors in the Rat. Frontiers in Neuroscience, 2021, 15, 682398.	1.4	1
804	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson's Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. Journal of Parkinson's Disease, 2021, 11, 1257-1269.	1.5	2
805	The role of neuroimaging in Parkinson's disease. Journal of Neurochemistry, 2021, 159, 660-689.	2.1	35
806	Molecular fMRI of neurochemical signaling. Journal of Neuroscience Methods, 2021, 364, 109372.	1.3	7
808	Dopamine release during psychological stress in euthymic bipolar I disorder: a Positron Emission Tomography study with [11C]raclopride. Journal of Affective Disorders, 2021, 295, 724-732.	2.0	0
809	Bias evaluation and reduction in 3D OP-OSEM reconstruction in dynamic equilibrium PET studies with 11C-labeled for binding potential analysis. PLoS ONE, 2021, 16, e0245580.	1.1	5
810	Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nature Neuroscience, 2011, 14, 257-262.	7.1	639
813	Stable and Unstable Activation of the Prefrontal Cortex with Dopaminergic Modulation. , 2007, , 235-246.		2
814	Chapter 24 Antipsychotic-Induced Changes in Striatal D2 Receptors in Schizophrenia: In Vivo Evidence from Dopamine Depletion Studies. , 2012, , 259-264.		1
815	Cortical and Sub-Cortical Effects in Primate Models of Cocaine Use: Implications for Addiction and the Increased Risk of Psychiatric Illness. , 2012, , 267-274.		1
816	1-Methyl-1,2,3,4-Tetrahydroisoquinoline: A Potent Neuroprotecting Agent. , 2012, , 45-56.		2
817	Imaging Tobacco Smoking with PET and SPECT. Current Topics in Behavioral Neurosciences, 2015, 24, 1-17.	0.8	20
818	Functional Brain Imaging and Drug Development. , 2004, , 95-107.		1
819	PET and SPECT Imaging of the Central Dopamine System in Humans. , 2014, , 229-248.		5
820	PET Imaging of Muscarinic Receptors. , 2014, , 445-464.		2
821	Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging. , 2014, , 465-512.		4

#	ARTICLE	IF	CITATIONS
822	Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 2003, , 215-227.	0.5	74
823	Molecular Imaging: The New Frontier in Neurotoxicology. , 2010, , 537-551.		1
824	Scatchard Analysis with Bolus/Infusion Administration of [11C]Raclopride. , 2002, , 63-69.		3
825	Molecular Imaging in Genetics. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 17-29.	0.5	3
826	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, , 1425-1439.	2.4	79
827	In Vivo Measurement of Receptor Density and Affinity: Comparison of the Routine Sequential Method With a Nonsequential Method in Studies of Dopamine D2 Receptors With [11C]Raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, , 280-284.	2.4	5
828	Imaging Human Mesolimbic Dopamine Transmission With Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, , 285-300.	2.4	119
829	In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT. <i>EJNMMI Research</i> , 2020, 10, 66.	1.1	2
830	- Gamma-Aminobutyric Acid Involvement in Depressive Illness: Interactions with Corticotropin-Releasing Hormone and Serotonin. , 2012, , 92-113.		6
831	Dopamine release, diffusion and uptake: A computational model for synaptic and volume transmission. <i>PLoS Computational Biology</i> , 2020, 16, e1008410.	1.5	17
832	Reproducibility of Post-Amphetamine [11C]FLB 457 Binding to Cortical D2/3 Receptors. <i>PLoS ONE</i> , 2013, 8, e76905.	1.1	17
833	Assessing Dopaminergic Neurotransmission with PET: Basic Theory and Applications in Alcohol Research. <i>Current Medical Imaging</i> , 2011, 7, 118-124.	0.4	10
834	Evidence from brain imaging studies for dopaminergic alterations in schizophrenia. , 2003, , 15-47.		2
835	Brain mechanisms of hallucinogens and entactogens. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 265-279.	1.8	97
836	Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. <i>Nuklearmedizin - NuclearMedicine</i> , 2016, 55, 21-28.	0.3	6
837	Gray Matter Volumes and Treatment Response of Psychotic Symptoms to Risperidone in Antipsychotic-Naïve Alzheimer's Disease Patients. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e8-e13.	1.1	4
838	Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET. <i>Neuropsychopharmacology</i> , 2022, 47, 1405-1412.	2.8	9
839	Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies. <i>Dialogues in Clinical Neuroscience</i> , 2000, 2, 359-372.	1.8	7

#	ARTICLE	IF	CITATIONS
840	Bolus Infusion of [11C]Raclopride. , 2002, , 77-82.		0
841	Imaging VS Postmortem Receptor Studies: What You See is What You Get?. Neurobiological Foundation of Aberrant Behaviors, 2002, , 37-48.	0.2	0
842	Measurements of Biochemical Reactions In Vivo. , 2003, , 3-29.		0
843	Can we measure 5-HT release with PET?. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S718-S718.	2.4	0
844	La asociaci3n entre la Escala de Sinceridad del Inventario de Personalidad de Maudsley y la disponibilidad de los receptores D2/D3 de dopamina estriatales de sujetos comunitarios chinos sanos. European Psychiatry (Ed Espa±ola), 2006, 13, 249-252.	0.0	0
845	Imaging vulnerability factors in addiction with PET and [11C]raclopride. , 2006, , 167-176.		0
846	Tomograf3a por emisi3n de fot3n 3nico. , 2008, , 127-154.		0
847	Studying Cognition with Positron Emission Tomography. On Thinking, 2009, , 39-50.	0.5	0
848	Molecular Imaging of the CNS: Drug Actions. , 2010, , 191-211.		0
849	In Vivo Imaging of Dopamine Receptors. Receptors, 2010, , 399-430.	0.2	0
850	10.1 Dopamine Dysfunction in Schizophrenia. , 2009, , 511-519.		1
852	Continuous Dopaminergic Stimulation in Parkinson's Disease - What Have We Learned from Positron-emission Tomography?. European Neurological Review, 2010, 5, 22.	0.5	0
853	GABAA Receptor Imaging by Positron Emission Tomography with [11C]flumazenil. Radioisotopes, 2010, 59, 49-58.	0.1	0
854	Challenges for PET Neuroimaging of Depressive Disorders. , 0, , .		0
855	Functional Imaging in Movement Disorders. , 2011, , 923-931.		1
856	Imaging in Neurology Research III: Focus on Neurotransmitter Imaging. , 2011, , 515-541.		1
858	Chapter 27 Antipsychotic-Induced Changes in Striatal D2 Receptors in Schizophrenia: In Vivo Evidence from Dopamine Depletion Studies. , 2013, , 293-298.		0
859	Positron Emission Tomography (PET) Imaging. , 2013, , 1-11.		0

#	ARTICLE	IF	CITATIONS
860	Cortical and Sub-Cortical Effects in Primate Models of Cocaine Use: Implications for Addiction and the Increased Risk of Psychiatric Illness. , 2013, , 319-326.		0
861	Minireview of Stereoselective Brain Imaging. Archives of Current Research International, 2014, 1, 1-16.	0.2	0
862	PET and SPECT Imaging in ADHD. , 2014, , 709-730.		1
863	Neuroimaging in Seasons and Winter Depression. , 2014, , 209-222.		0
864	Pharmacological Interventions That Have the Potential to Alter Neurotransmitter Levels in the Human Brain. , 2014, , 45-63.		0
865	Imaging of the Antidepressant Drug Response Using SPECT and PET. , 2014, , 325-345.		0
866	The Influence of Pain on Reward Processing: Current Literature and Prospects. , 2014, , 31-48.		3
867	Imaging of Muscarinic Receptors in the Central Nervous System. Neuromethods, 2016, , 181-203.	0.2	0
868	Anxiety in children with hyperkinetic disorder (literature review). V M Bekhterev Review of Psychiatry and Medical Psychology, 2019, , 3-12.	0.1	0
869	Fronto-striatal dopamine D2 receptor availability is associated with cognitive variability in older individuals with low dopamine integrity. Scientific Reports, 2021, 11, 21089.	1.6	1
870	PET and PET/MRI Methods. , 2020, , 125-143.		0
871	Neuroimaging in Seasons and Winter Depression. , 2021, , 245-259.		0
872	PET and SPECT Imaging in ADHD. , 2021, , 949-970.		0
873	Functional Human Brain Mapping. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 198-212.	0.1	0
874	Maternal dopamine encodes affective signals of human infants. Social Cognitive and Affective Neuroscience, 2022, 17, 503-509.	1.5	3
875	GABAergic and glutamatergic effects on nigrostriatal and mesolimbic dopamine release in the rat. Reviews in the Neurosciences, 2020, 31, 569-588.	1.4	1
876	Radiochemistry and Radiopharmacy. , 2007, , 34-76.		1
877	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Neurotherapeutics, 2005, 2, 226-236.	2.1	0



#	ARTICLE	IF	CITATIONS
880	Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?. <i>World Psychiatry</i> , 2003, 2, 166-71.	4.8	43
881	Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 86-102.	1.4	200
883	Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 247-60.	1.0	14
884	Microfluidics for positron emission tomography probe development. <i>Molecular Imaging</i> , 2010, 9, 175-91.	0.7	15
885	Dissecting Motor and Cognitive Component Processes of a Finger-Tapping Task With Hybrid Dopamine Positron Emission Tomography and Functional Magnetic Resonance Imaging. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 733091.	1.0	4
886	Dopamine, Cognitive Flexibility, and IQ: Epistatic Catechol-O-Methyltransferase:DRD2 Gene-Gene Interactions Modulate Mental Rigidity. <i>Journal of Cognitive Neuroscience</i> , 2021, 34, 153-179.	1.1	6
889	Insight Into the Effects of Clinical Repetitive Transcranial Magnetic Stimulation on the Brain From Positron Emission Tomography and Magnetic Resonance Imaging Studies: A Narrative Review. <i>Frontiers in Neuroscience</i> , 2022, 16, 787403.	1.4	11
890	PET as a Translational Tool in Drug Development for Neuroscience Compounds. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 774-785.	2.3	7
891	Atlas of type 2 dopamine receptors in the human brain: Age and sex dependent variability in a large PET cohort. <i>NeuroImage</i> , 2022, 255, 119149.	2.1	8
892	The 5-HT1A receptor antagonist WAY-100635 decreases motor/exploratory behaviors and nigrostriatal and mesolimbocortical dopamine D2/3 receptor binding in adult rats. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 215, 173363.	1.3	1
893	High-resolution and high-sensitivity PET for quantitative molecular imaging of the monoaminergic nuclei: A GATE simulation study. <i>Medical Physics</i> , 2022, 49, 4430-4444.	1.6	7
894	Perspectives of brain imaging with PET systems. <i>Bio-Algorithms and Med-Systems</i> , 2022, 17, 269-291.	1.0	4
900	Continuous but not intermittent theta burst stimulation decreases striatal dopamine release and cortical excitability. <i>Experimental Neurology</i> , 2022, 354, 114106.	2.0	3
901	Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. <i>Biological Psychiatry</i> , 2022, 92, 791-799.	0.7	17
904	Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders. <i>Journal of Neurochemistry</i> , 2023, 164, 401-443.	2.1	2
905	Measurement of Striatal Dopamine Release Induced by Neuropsychological Stimulation in Positron Emission Tomography With Dual Injections of [11C]Raclopride. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	0
906	Brain-iron deficiency models of restless legs syndrome. <i>Experimental Neurology</i> , 2022, 356, 114158.	2.0	16
907	Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	3

#	ARTICLE	IF	CITATIONS
908	Changing Cerebral Blood Flow, Glucose Metabolism, and Dopamine Binding Through Transcranial Magnetic Stimulation: A Systematic Review of Transcranial Magnetic Stimulation-Positron Emission Tomography Literature. <i>Pharmacological Reviews</i> , 2022, 74, 918-932.	7.1	9
910	PET Quantification and Kinetic Analysis. , 2023, , 183-194.		0